RecentMedicalFindings.com
Summarizing relevant biomedical research!
polypharmacy     Bookmark and Share
Search webpages of this site (RecentMedicalFindings):
Didn't find what you wanted? Try it at BioMedLib™ !
Search directly on the biomedical articles using BioMedLib™ search engine:



1. Biomedical articles (top 50; 2010 to 2015)
1. Ballon J, Stroup TS: Polypharmacy for schizophrenia. Curr Opin Psychiatry; 2013 Mar;26(2):208-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy for schizophrenia.
  • This review provides an update on evidence regarding the effectiveness of polypharmacy approaches.
  • RECENT FINDINGS: Epidemiology studies have demonstrated that polypharmacy is extremely common, but evidence regarding all polypharmacy approaches for schizophrenia from randomized controlled trials remains scarce.
  • [MeSH-major] Antidepressive Agents / therapeutic use. Antipsychotic Agents / therapeutic use. Benzodiazepines / therapeutic use. Polypharmacy. Schizophrenia / drug therapy

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cochrane Database Syst Rev. 2002;(2):CD002305 [12076447.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1209-23 [16172203.001]
  • [Cites] Neuropsychopharmacology. 2003 Jan;28(1):182-92 [12496955.001]
  • [Cites] Schizophr Bull. 2003;29(3):531-40 [14609246.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD005581 [16856105.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD005962 [17054266.001]
  • [Cites] Acta Psychiatr Scand. 2007 Feb;115(2):101-5 [17244173.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD006391 [17253592.001]
  • [Cites] Schizophr Res. 2007 May;92(1-3):68-73 [17336500.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD001258 [17636660.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD003834 [17636738.001]
  • [Cites] Fundam Clin Pharmacol. 2008 Jun;22(3):323-33 [18485151.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(3):CD004028 [18646098.001]
  • [Cites] Schizophr Bull. 2009 Mar;35(2):443-57 [18417466.001]
  • [Cites] J Clin Psychiatry. 2009 Jul;70(7):1041-50 [19653979.001]
  • [Cites] Schizophr Bull. 2010 Jan;36(1):71-93 [19955390.001]
  • [Cites] Schizophr Res. 2010 May;118(1-3):218-23 [20207521.001]
  • [Cites] Psychiatry Res. 2010 Aug 30;179(1):19-23 [20472299.001]
  • [Cites] Int J Neuropsychopharmacol. 2010 Sep;13(8):1115-25 [20459883.001]
  • [Cites] Br J Psychiatry. 2010 Sep;197(3):174-9 [20807960.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):208-11 [21095214.001]
  • [Cites] Br J Clin Pharmacol. 2011 Mar;71(3):377-82 [21284696.001]
  • [Cites] Schizophr Res. 2011 Apr;127(1-3):93-9 [21262565.001]
  • [Cites] J Clin Psychiatry. 2011 Mar;72(3):326-30 [20816037.001]
  • [Cites] J Psychopharmacol. 2011 May;25(5):667-74 [20615930.001]
  • [Cites] J Clin Psychopharmacol. 2011 Jun;31(3):266-73 [21508849.001]
  • [Cites] Nature. 2011 Jun 16;474(7351):277-8 [21677725.001]
  • [Cites] Am J Psychiatry. 2011 Jul;168(7):702-8 [21536693.001]
  • [Cites] Psychiatr Serv. 2011 Aug;62(8):908-14 [21807830.001]
  • [Cites] BMC Psychiatry. 2011;11:118 [21791046.001]
  • [Cites] Int Clin Psychopharmacol. 2011 Nov;26(6):311-5 [21849905.001]
  • [Cites] Int Clin Psychopharmacol. 2011 Nov;26(6):303-10 [21934625.001]
  • [Cites] Eur Neuropsychopharmacol. 2012 Mar;22(3):165-82 [21906915.001]
  • [Cites] J Clin Psychopharmacol. 2012 Apr;32(2):165-72 [22367654.001]
  • [Cites] Arch Gen Psychiatry. 2012 May;69(5):476-83 [22566579.001]
  • [Cites] Expert Opin Drug Saf. 2012 Jul;11(4):527-42 [22563628.001]
  • [Cites] Acta Psychiatr Scand. 2002 Nov;106(5):323-30 [12366465.001]
  • (PMID = 23318662.001).
  • [ISSN] 1473-6578
  • [Journal-full-title] Current opinion in psychiatry
  • [ISO-abbreviation] Curr Opin Psychiatry
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / KM1 CA156709; United States / NCI NIH HHS / CA / KM1 CA156709
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antipsychotic Agents; 12794-10-4 / Benzodiazepines
  • [Other-IDs] NLM/ NIHMS574232; NLM/ PMC4026924
  •  go-up   go-down


2. Dussias P, Kalali AH, Citrome L: Polypharmacy of schizophrenia. Psychiatry (Edgmont); 2010 Aug;7(8):17-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy of schizophrenia.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20877529.001).
  • [ISSN] 1555-5194
  • [Journal-full-title] Psychiatry (Edgmont (Pa. : Township))
  • [ISO-abbreviation] Psychiatry (Edgmont)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2945852
  • [Keywords] NOTNLM ; Schizophrenia / antidepressants / antipsychotics / extrapyramidal symptoms / mood stabilizers
  •  go-up   go-down


3. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH, Schizophrenia Trials Network: Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry; 2011 Jul;168(7):702-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
  • OBJECTIVE: This randomized trial addressed the risks and benefits of staying on antipsychotic polypharmacy or switching to monotherapy.
  • METHOD: Adult outpatients with schizophrenia taking two antipsychotics (127 participants across 19 sites) were randomly assigned to stay on polypharmacy or switch to monotherapy by discontinuing one antipsychotic.
  • RESULTS: Patients assigned to switch to monotherapy had shorter times to all-cause treatment discontinuation than those assigned to stay on polypharmacy.
  • By month 6, 86% (N=48) of those assigned to stay on polypharmacy were still taking both medications, whereas 69% (N=40) of those assigned to switch to monotherapy were still taking the same medication.
  • Most monotherapy discontinuations entailed returning to the original polypharmacy.
  • On average, the monotherapy group lost weight, whereas the polypharmacy group gained weight.
  • These results support the reasonableness of prescribing guidelines encouraging trials of antipsychotic monotherapy for individuals receiving antipsychotic polypharmacy, with the caveat that patients should be free to return to polypharmacy if an adequate trial on antipsychotic monotherapy proves unsatisfactory.
  • [MeSH-major] Antipsychotic Agents / therapeutic use. Polypharmacy. Schizophrenia / drug therapy

  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. See the articles recommended by F1000Prime's Faculty of more than 5,000 expert scientists and clinical researchers. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Psychiatry. 2002 Nov;159(11):1932-5 [12411232.001]
  • [Cites] Schizophr Bull. 2002;28(1):75-84 [12047024.001]
  • [Cites] Am J Psychiatry. 2003 Jun;160(6):1125-32 [12777271.001]
  • [Cites] Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56 [15000267.001]
  • [Cites] J Clin Psychiatry. 2004 Apr;65(4):500-8 [15119912.001]
  • [Cites] Int J Neuropsychopharmacol. 2004 Jun;7(2):133-42 [14741059.001]
  • [Cites] Am J Psychiatry. 2004 Aug;161(8):1334-49 [15285957.001]
  • [Cites] J Clin Psychiatry. 2004 Oct;65(10):1377-88 [15491242.001]
  • [Cites] Acta Psychiatr Scand Suppl. 1970;212:11-9 [4917967.001]
  • [Cites] Arch Gen Psychiatry. 1982 Apr;39(4):486-7 [6121550.001]
  • [Cites] Schizophr Bull. 1987;13(2):261-76 [3616518.001]
  • [Cites] Psychopharmacol Bull. 1988;24(4):603-7 [3074321.001]
  • [Cites] J Clin Psychiatry. 1997 Dec;58(12):538-46 [9448657.001]
  • [Cites] Br J Psychiatry. 1997 Dec;171:569-73 [9519099.001]
  • [Cites] Am J Psychiatry. 2005 Jan;162(1):130-6 [15625211.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1209-23 [16172203.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):472-82 [16452559.001]
  • [Cites] Am J Psychiatry. 2006 Dec;163(12):2090-5 [17151159.001]
  • [Cites] Schizophr Res. 2007 May;92(1-3):90-4 [17321111.001]
  • [Cites] Schizophr Bull. 2009 Mar;35(2):443-57 [18417466.001]
  • [Cites] Psychiatr Serv. 2009 Dec;60(12):1595-602 [19952148.001]
  • [Cites] Schizophr Bull. 2010 Jan;36(1):71-93 [19955390.001]
  • [Cites] Biol Psychiatry. 2010 Feb 1;67(3):255-62 [19897178.001]
  • [Cites] Am J Psychiatry. 2010 Jun;167(6):686-93 [20360319.001]
  • [Cites] J Clin Psychiatry. 2005 Jan;66(1):63-72 [15669890.001]
  • [Cites] Psychiatr Serv. 2003 Jan;54(1):55-9 [12509667.001]
  • [Cites] J Sex Marital Ther. 2000 Jan-Mar;26(1):25-40 [10693114.001]
  • [CommentIn] Am J Psychiatry. 2011 Jul;168(7):667-9 [21724670.001]
  • [CommentIn] Am J Psychiatry. 2011 Oct;168(10):1117; author reply 1117 [21969048.001]
  • (PMID = 21536693.001).
  • [ISSN] 1535-7228
  • [Journal-full-title] The American journal of psychiatry
  • [ISO-abbreviation] Am J Psychiatry
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00044655
  • [Grant] United States / NIMH NIH HHS / MH / MH59312; United States / NIMH NIH HHS / MH / MH900001; United States / NIMH NIH HHS / MH / N01MH90001; United States / NIMH NIH HHS / MH / R01 MH059312
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Other-IDs] NLM/ NIHMS494901; NLM/ PMC3739691
  • [Investigator] Adler L; Byerly M; Caroff S; Csernansky J; D'Souza C; Jackson C; Peters JJ; Manschreck T; McEvoy J; Miller A; Nasrallah H; Olson S; Patel J; Saltz B; Steinbook RM; Tapp A; Marcus K
  •  go-up   go-down


Advertisement
4. Maher RL, Hanlon J, Hajjar ER: Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf; 2014 Jan;13(1):57-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical consequences of polypharmacy in elderly.
  • INTRODUCTION: Polypharmacy, defined as the use of multiple drugs or more than are medically necessary, is a growing concern for older adults.
  • AREAS COVERED: We present information about: i) prevalence of polypharmacy and unnecessary medication use;.
  • ii) negative consequences of polypharmacy; and iii) interventions to improve polypharmacy.
  • EXPERT OPINION: International research shows that polypharmacy is common in older adults with the highest number of drugs taken by those residing in nursing homes.
  • Research has clearly established a strong relationship between polypharmacy and negative clinical consequences.
  • Moreover, well-designed interprofessional (often including clinical pharmacist) intervention studies that focus on enrolling high-risk older patients with polypharmacy have shown that they can be effective in reducing aspects of unnecessary prescribing with mixed results on distal health outcomes.
  • [MeSH-major] Inappropriate Prescribing / prevention & control. Physician's Practice Patterns / standards. Polypharmacy

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Patient Saf. 2009 Jun;5(2):61-6 [19920442.001]
  • [Cites] JAMA. 2008 Dec 24;300(24):2867-78 [19109115.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Apr;8(2):146-60 [20439064.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Jun;8(3):183-200 [20624609.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Jun;8(3):215-24 [20624611.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):901-10 [20623513.001]
  • [Cites] JAMA. 2010 Oct 13;304(14):1592-601 [20940385.001]
  • [Cites] Drugs Aging. 2011 Apr 1;28(4):315-23 [21428466.001]
  • [Cites] Eur J Clin Pharmacol. 2011 May;67(5):507-19 [21221958.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2011 May;20(5):514-22 [21308855.001]
  • [Cites] Neurourol Urodyn. 2011 Sep;30(7):1286-90 [21538498.001]
  • [Cites] Geriatr Gerontol Int. 2011 Oct;11(4):438-44 [21545384.001]
  • [Cites] J Am Geriatr Soc. 2012 Jan;60(1):34-41 [22150441.001]
  • [Cites] J Am Med Dir Assoc. 2012 Mar;13(3):309.e15-21 [21839687.001]
  • [Cites] Cochrane Database Syst Rev. 2012;5:CD008165 [22592727.001]
  • [Cites] Health Policy. 2013 Feb;109(2):166-74 [23195435.001]
  • [Cites] BMC Geriatr. 2013;13:6 [23320746.001]
  • [Cites] Ann Pharmacother. 2013 Mar;47(3):324-32 [23482734.001]
  • [Cites] J Am Geriatr Soc. 2013 Mar;61(3):371-9 [23452034.001]
  • [Cites] Drugs Aging. 2013 May;30(5):285-307 [23475597.001]
  • [Cites] Geriatr Gerontol Int. 2013 Oct;13(4):978-85 [23452137.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Feb;8(1):63-72 [20226393.001]
  • [Cites] Int Psychogeriatr. 2000 Mar;12(1):117-27 [10798458.001]
  • [Cites] Age Ageing. 2001 May;30(3):205-11 [11443021.001]
  • [Cites] J Clin Epidemiol. 2001 Aug;54(8):837-44 [11470394.001]
  • [Cites] Ann Emerg Med. 2001 Dec;38(6):666-71 [11719747.001]
  • [Cites] JAMA. 2003 Mar 5;289(9):1107-16 [12622580.001]
  • [Cites] JAMA. 2003 Apr 2;289(13):1652-8 [12672733.001]
  • [Cites] Drugs Aging. 2003;20(11):817-32 [12964888.001]
  • [Cites] Age Ageing. 2004 Jan;33(1):58-65 [14695865.001]
  • [Cites] Ann Pharmacother. 2004 Feb;38(2):303-12 [14742770.001]
  • [Cites] Am J Med. 2004 Mar 15;116(6):394-401 [15006588.001]
  • [Cites] Age Ageing. 2004 Nov;33(6):612-7 [15385274.001]
  • [Cites] J Gen Intern Med. 1993 May;8(5):278-83 [8505690.001]
  • [Cites] Am J Med. 1996 Apr;100(4):428-37 [8610730.001]
  • [Cites] Ann Pharmacother. 2005 Mar;39(3):412-7 [15687479.001]
  • [Cites] Am J Geriatr Pharmacother. 2004 Dec;2(4):257-64 [15903284.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):716-24 [16091574.001]
  • [Cites] J Am Geriatr Soc. 2005 Sep;53(9):1518-23 [16137281.001]
  • [Cites] Scand J Prim Health Care. 2005 Dec;23(4):209-14 [16272068.001]
  • [Cites] Am J Geriatr Pharmacother. 2006 Mar;4(1):36-41 [16730619.001]
  • [Cites] Clin Ther. 2006 Aug;28(8):1133-43 [16982290.001]
  • [Cites] J Am Geriatr Soc. 2007 May;55(5):658-65 [17493184.001]
  • [Cites] Lancet. 2007 Jul 14;370(9582):185-91 [17630042.001]
  • [Cites] Expert Opin Drug Saf. 2007 Nov;6(6):695-704 [17967158.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Dec;5(4):317-23 [18179989.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Dec;5(4):345-51 [18179993.001]
  • (PMID = 24073682.001).
  • [ISSN] 1744-764X
  • [Journal-full-title] Expert opinion on drug safety
  • [ISO-abbreviation] Expert Opin Drug Saf
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / K07 AG033174; United States / NIA NIH HHS / AG / K07AG033174; United States / AHRQ HHS / HS / K12 HS019461; United States / NIA NIH HHS / AG / P30 AG024827; United States / NIA NIH HHS / AG / P30AG024827; United States / NIA NIH HHS / AG / R01 AG027017; United States / AHRQ HHS / HS / R01 HS018721; United States / NIA NIH HHS / AG / R01AG027017; United States / NIA NIH HHS / AG / R01AG037451; United States / NIA NIH HHS / AG / T32 AG021885; United States / NIA NIH HHS / AG / T32AG021885
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS484047; NLM/ PMC3864987
  •  go-up   go-down


5. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU: Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf; 2012 Jul;11(4):527-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and tolerability of antipsychotic polypharmacy.
  • INTRODUCTION: Antipsychotic polypharmacy (APP), the concomitant use of ≥ 2 antipsychotics, is common in clinical practice.
  • [MeSH-major] Antipsychotic Agents / adverse effects. Polypharmacy

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Schizophr Res. 2010 Jan;116(1):35-43 [19892525.001]
  • [Cites] Curr Opin Psychiatry. 2010 Mar;23(2):103-11 [20051861.001]
  • [Cites] Curr Drug Saf. 2010 Jan;5(1):97-104 [20210726.001]
  • [Cites] J Clin Psychiatry. 2010 May;71(5):566-73 [20361903.001]
  • [Cites] J Psychopharmacol. 2010 Jul;24(7):1037-44 [19164494.001]
  • [Cites] Ann Pharmacother. 2010 Jul-Aug;44(7-8):1171-80 [20587746.001]
  • [Cites] Eur Psychiatry. 2010 Jun;25 Suppl 2:S12-21 [20620881.001]
  • [Cites] Int J Neuropsychopharmacol. 2010 Sep;13(8):1115-25 [20459883.001]
  • [Cites] Pharmacopsychiatry. 2010 Aug;43(6):216-20 [20589598.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1333-41 [20691745.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1167-9 [16647796.001]
  • [Cites] J Clin Psychopharmacol. 2010 Oct;30(5):518-25 [20814315.001]
  • [Cites] Eur J Clin Pharmacol. 1999 Nov;55(9):685-90 [10638400.001]
  • [Cites] Drug Saf. 2000 Jan;22(1):73-81 [10647977.001]
  • [Cites] J Clin Psychiatry. 2000;61 Suppl 4:5-9 [10739324.001]
  • [Cites] Ann Pharmacother. 2000 May;34(5):662-5 [10852096.001]
  • [Cites] Drug Saf. 2000 Sep;23(3):215-28 [11005704.001]
  • [Cites] Can J Psychiatry. 2001 May;46(4):334-9 [11387789.001]
  • [Cites] J Clin Psychiatry. 2001 Aug;62(8):605-8 [11561931.001]
  • [Cites] J Clin Psychiatry. 2001;62 Suppl 23:23-9 [11603882.001]
  • [Cites] J Clin Psychiatry. 2002 Feb;63(2):93-4 [11874226.001]
  • [Cites] Acta Psychiatr Scand. 2006 Feb;113(2):135-41 [16423165.001]
  • [Cites] Acta Psychiatr Scand. 2006 Feb;113(2):142-7 [16423166.001]
  • [Cites] Br J Psychiatry. 2006 Feb;188:122-7 [16449697.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):472-82 [16452559.001]
  • [Cites] J Clin Psychopharmacol. 2010 Oct;30(5):596-9 [20814333.001]
  • [Cites] Br J Psychiatry. 2010 Oct;197(4):266-71 [20884948.001]
  • [Cites] Acta Psychiatr Scand. 2010 Nov;122(5):356-66 [20528803.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1495-9 [20732372.001]
  • [Cites] Aust N Z J Psychiatry. 2011 Jan;45(1):89 [21058927.001]
  • [Cites] Trends Mol Med. 2011 Feb;17(2):97-107 [21185230.001]
  • [Cites] J Clin Psychiatry. 2011 Feb;72(2):240-7 [20868629.001]
  • [Cites] Am J Psychiatry. 2011 Jul;168(7):702-8 [21536693.001]
  • [Cites] BMC Psychiatry. 2011;11:118 [21791046.001]
  • [Cites] Schizophr Res. 2011 Sep;131(1-3):58-62 [21419603.001]
  • [Cites] Nord J Psychiatry. 2011 Oct;65(5):345-52 [21428861.001]
  • [Cites] Eur J Health Econ. 2012 Jun;13(3):355-63 [21452062.001]
  • [Cites] Schizophr Res. 2012 Jun;138(1):18-28 [22534420.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Aug 1;214(3):326-34 [16510162.001]
  • [Cites] Psychiatr Serv. 2006 Aug;57(8):1094-101 [16870959.001]
  • [Cites] Schizophr Res. 2006 Sep;86(1-3):138-46 [16793238.001]
  • [Cites] Int Clin Psychopharmacol. 2006 Nov;21(6):355-62 [17012982.001]
  • [Cites] Schizophr Res. 2007 Jan;89(1-3):91-100 [17070017.001]
  • [Cites] Curr Opin Psychiatry. 2007 Mar;20(2):138-42 [17278911.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3456-9 [17360666.001]
  • [Cites] J Psychiatr Pract. 2007 Mar;13(2):129-37 [17414692.001]
  • [Cites] Psychiatr Serv. 2007 Apr;58(4):489-95 [17412850.001]
  • [Cites] Pharmacopsychiatry. 2007 Mar;40(2):47-52 [17447172.001]
  • [Cites] Am J Psychiatry. 2007 Jun;164(6):870-6 [17541044.001]
  • [Cites] Aust N Z J Psychiatry. 2007 Jul;41(7):606-10 [17558623.001]
  • [Cites] J Psychopharmacol. 2007 Jun;21(4):453-6 [17050662.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1255-60 [17600607.001]
  • [Cites] Psychiatry Res. 2007 Aug 30;152(2-3):165-72 [17445906.001]
  • [Cites] Am J Psychiatry. 2007 Sep;164(9):1404-10 [17728426.001]
  • [Cites] CNS Spectr. 2007 Sep;12(9 Suppl 14):1-13 [17805218.001]
  • [Cites] Compr Psychiatry. 2008 Jan-Feb;49(1):65-9 [18063043.001]
  • [Cites] Schizophr Res. 2008 Jan;98(1-3):323-4 [17950576.001]
  • [Cites] Hum Psychopharmacol. 2008 Jun;23(4):283-90 [18302312.001]
  • [Cites] J Psychopharmacol. 2008 May;22(3):244-53 [18308789.001]
  • [Cites] Br J Psychiatry. 2003 Mar;182:199-204 [12611781.001]
  • [Cites] J Clin Psychopharmacol. 2003 Jun;23(3 Suppl 1):S21-6 [12832946.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):361-9 [14751434.001]
  • [Cites] Am J Psychiatry. 2004 Apr;161(4):700-6 [15056517.001]
  • [Cites] Br J Clin Pharmacol. 2004 Aug;58(2):178-83 [15255800.001]
  • [Cites] Br J Psychiatry. 2004 Aug;185:152-6 [15286067.001]
  • [Cites] Psychiatr Serv. 2004 Sep;55(9):1006-13 [15345760.001]
  • [Cites] J Clin Psychiatry. 2004 Oct;65(10):1377-88 [15491242.001]
  • [Cites] Dis Nerv Syst. 1977 Jul;38(7):541-5 [17517.001]
  • [Cites] Psychopharmacology (Berl). 1986;88(4):403-19 [2871578.001]
  • [Cites] Br J Psychiatry. 1987 Jan;150:88-91 [3115352.001]
  • [Cites] Psychiatry Res. 1991 Jun;37(3):297-308 [1679950.001]
  • [Cites] Br J Psychiatry Suppl. 1992 May;(17):54-9 [1358128.001]
  • [Cites] Br J Clin Pharmacol. 1995 Nov;40(5):467-76 [8703651.001]
  • [Cites] J Clin Psychopharmacol. 1997 Aug;17(4):314-7 [9241012.001]
  • [Cites] Br J Psychiatry. 1997 Dec;171:569-73 [9519099.001]
  • [Cites] Am J Psychiatry. 1998 Sep;155(9):1207-13 [9734544.001]
  • [Cites] J Clin Psychiatry. 1996 Sep;57(9):395-7 [9746446.001]
  • [Cites] Br J Psychiatry. 1998 Oct;173:325-9 [9926037.001]
  • [Cites] Schizophr Res. 1999 Mar 1;35 Suppl:S67-73 [10190227.001]
  • [Cites] Actas Esp Psiquiatr. 2004 Nov-Dec;32(6):333-9 [15529221.001]
  • [Cites] J Clin Psychiatry. 2004 Nov;65(11):1491-8 [15554761.001]
  • [Cites] J Clin Psychiatry. 2005 Jan;66(1):63-72 [15669890.001]
  • [Cites] Aust N Z J Psychiatry. 2005 Sep;39(9):840-1 [16168043.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1209-23 [16172203.001]
  • [Cites] Clin Neuropharmacol. 2005 Sep-Oct;28(5):220-4 [16239761.001]
  • [Cites] Drug Metab Pharmacokinet. 2005 Oct;20(5):368-78 [16272755.001]
  • [Cites] Int Clin Psychopharmacol. 2006 Mar;21(2):99-103 [16421461.001]
  • [Cites] J Clin Psychiatry. 2005 Nov;66(11):1386-91 [16420075.001]
  • [Cites] J Clin Psychiatry. 2008 May;69(5):720-31 [18370574.001]
  • [Cites] Jt Comm J Qual Patient Saf. 2008 Oct;34(10):571-82 [18947117.001]
  • [Cites] N Engl J Med. 2009 Jan 15;360(3):225-35 [19144938.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2009 Feb;259(1):23-7 [18574608.001]
  • [Cites] Schizophr Bull. 2009 Mar;35(2):443-57 [18417466.001]
  • [Cites] Schizophr Bull. 2009 Mar;35(2):458-68 [18436527.001]
  • [Cites] Hum Psychopharmacol. 2009 Apr;24(3):225-32 [19283774.001]
  • [Cites] J Psychopharmacol. 2009 May;23(3):305-14 [18562423.001]
  • [Cites] Eur Neuropsychopharmacol. 2009 Jul;19(7):520-32 [19411165.001]
  • [Cites] J Clin Psychopharmacol. 2009 Apr;29(2):165-9 [19512978.001]
  • [Cites] Lancet. 2009 Aug 22;374(9690):620-7 [19595447.001]
  • [Cites] Am J Psychiatry. 2009 Sep;166(9):1055-62 [19570929.001]
  • [Cites] JAMA. 2009 Oct 28;302(16):1765-73 [19861668.001]
  • [Cites] J Clin Psychiatry. 2009 Oct;70(10):1348-57 [19906340.001]
  • (PMID = 22563628.001).
  • [ISSN] 1744-764X
  • [Journal-full-title] Expert opinion on drug safety
  • [ISO-abbreviation] Expert Opin Drug Saf
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / P30 MH090590-03
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Other-IDs] NLM/ NIHMS369312; NLM/ PMC3384511
  •  go-up   go-down


6. Kim HA, Shin JY, Kim MH, Park BJ: Prevalence and predictors of polypharmacy among Korean elderly. PLoS One; 2014;9(6):e98043
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and predictors of polypharmacy among Korean elderly.
  • OBJECTIVE: Polypharmacy is widespread in the elderly because of their multiple chronic health problems.
  • The objective of this study was to investigate the prevalence and predictors associated with polypharmacy in a nationally representative sample of Korean elderly individuals.
  • We defined 'polypharmacy' as the concurrent use of 6 medications or more per person, 'major polypharmacy' as 11 medications or more, and 'excessive polypharmacy' as 21 medications or more.
  • The frequency and proportion (%) and their 95% confidence intervals were presented according to the polypharmacy definition.
  • Polypharmacy was visualized by the Quantum Geographic Information Systems (QGIS) program to describe regional differences in patterns of drug use.
  • Multivariate ordinal logistic regression was performed to estimate odds ratios (ORs) and their 95% confidence intervals (CI) to investigate the risk factors for polypharmacy.
  • RESULTS: Of the Korean elderly studied, 86.4% had polypharmacy, 44.9% had major polypharmacy and 3.0% had excessive polypharmacy.
  • Polypharmacy was found to be primarily concentrated in the Southwest region of the country.
  • Significant associations between polypharmacy and the lower-income Medical Aid population (OR = 1.52, 95% CI 1.47, 1.56) compared with National Health Insurance patients was observed.
  • CONCLUSIONS: Nationwide efforts are needed for managing polypharmacy among Korean elderly patients.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Pharmacother. 2001 Sep;35(9):1004-9 [11573845.001]
  • [Cites] J Korean Acad Nurs. 2012 Dec;42(7):928-35 [23377588.001]
  • [Cites] J Women Aging. 2001;13(4):39-51 [11876433.001]
  • [Cites] J Clin Epidemiol. 2002 Aug;55(8):809-17 [12384196.001]
  • [Cites] Br J Clin Pharmacol. 2004 Jan;57(1):6-14 [14678335.001]
  • [Cites] J Am Geriatr Soc. 2004 Aug;52(8):1349-54 [15271125.001]
  • [Cites] Int J Qual Health Care. 1994 Dec;6(4):371-81 [7719673.001]
  • [Cites] J Gen Intern Med. 1995 Apr;10(4):199-205 [7790981.001]
  • [Cites] AACN Clin Issues. 1997 Nov;8(4):627-34 [9392719.001]
  • [Cites] Eur J Clin Pharmacol. 1998 May;54(3):197-202 [9681659.001]
  • [Cites] Eur J Clin Pharmacol. 1999 Sep;55(7):533-6 [10501824.001]
  • [Cites] JAMA. 2005 Mar 16;293(11):1348-58 [15769968.001]
  • [Cites] J Am Acad Nurse Pract. 2005 Apr;17(4):123-32 [15819637.001]
  • [Cites] J Gerontol Nurs. 2005 Sep;31(9):4-11 [16190007.001]
  • [Cites] Expert Opin Drug Saf. 2014 Jan;13(1):57-65 [24073682.001]
  • [Cites] Eur J Clin Pharmacol. 2006 Feb;62(2):151-8 [16408226.001]
  • [Cites] Res Social Adm Pharm. 2005 Sep;1(3):446-59 [17138489.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Jun;5(2):147-61 [17719517.001]
  • [Cites] Int J Clin Pharmacol Ther. 2007 Dec;45(12):643-53 [18184532.001]
  • [Cites] Rev Panam Salud Publica. 2008 Jan;23(1):34-43 [18291071.001]
  • [Cites] Ann Pharmacother. 2008 Jun;42(6):783-9 [18445704.001]
  • [Cites] Clin Interv Aging. 2008;3(2):383-9 [18686760.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):327-34 [19180586.001]
  • [Cites] Drugs Aging. 2009;26(4):345-54 [19476401.001]
  • [Cites] Drugs Aging. 2009;26(6):493-503 [19591524.001]
  • [Cites] Drugs Aging. 2009;26(12):1029-38 [19929030.001]
  • [Cites] Drugs Aging. 2009;26(12):1039-48 [19929031.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1206-13 [19795368.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Feb;8(1):63-72 [20226393.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2010 Apr;19(4):375-83 [20191596.001]
  • [Cites] BMC Public Health. 2011;11:101 [21320345.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2011 May;20(5):488-96 [21264988.001]
  • [Cites] J Korean Med Sci. 2011 Nov;26(11):1461-8 [22065902.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):337-44 [11790213.001]
  • (PMID = 24915073.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4051604
  •  go-up   go-down


7. Kojima G, Bell C, Tamura B, Inaba M, Lubimir K, Blanchette PL, Iwasaki W, Masaki K: Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. J Am Med Dir Assoc; 2012 Nov;13(9):818.e11-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing cost by reducing polypharmacy: the polypharmacy outcomes project.
  • OBJECTIVE: To examine the effect of intervention by geriatric medicine fellows and a geriatrician on medication cost among long term care residents with polypharmacy.
  • PARTICIPANTS: Long term care residents with polypharmacy, defined as being on 9 or more medications.
  • INTERVENTION: Medication lists of all nursing home residents were reviewed in October 2007 by geriatric medicine fellows and a faculty geriatrician using the 2003 Beers Criteria and the Epocrates online drug-drug interaction program.
  • Recommendations for each resident were prepared and discussed directly with their primary physicians, who made the final decisions regarding medication discontinuation or taper.
  • Estimated reduction in nursing administration time and cost were calculated based on published literature on medication administration time and nursing labor costs.
  • After the intervention, mean monthly medication costs per resident significantly decreased; overall medications, from $874.27 to $843.56 (P < .0001); scheduled medications, from $814.05 to $801.14 (P= .007); PRN medications, from $60.22 to $42.43 (P < .0001).
  • Gastrointestinal medications demonstrated the highest cost savings of all medication categories (eg, promethazine and proton pump inhibitors), followed by central nervous system-active medications (including benzodiazepines and fluoxetine), then analgesics and diabetes medications.
  • CONCLUSION: This polypharmacy reduction intervention by physicians used readily available tools, demonstrated a significant decrease in medication-related costs, and provided training in the core competencies of practice-based learning and improvement and systems-based practice to geriatric medicine fellows in long term care.
  • [MeSH-major] Nursing Homes / economics. Polypharmacy

  • MedlinePlus Health Information. consumer health - Nursing Homes.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 American Medical Directors Association, Inc. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Nutr Health Aging. 1997;1(3):181-4 [10995088.001]
  • [Cites] Geriatr Gerontol Int. 2012 Jul;12(3):425-30 [22212467.001]
  • [Cites] J Am Geriatr Soc. 2002 Dec;50(12):1962-8 [12473007.001]
  • [Cites] Arch Intern Med. 2003 Dec 8-22;163(22):2716-24 [14662625.001]
  • [Cites] Health Serv Res. 2004 Oct;39(5):1257-76 [15333108.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1825-32 [1888249.001]
  • [Cites] Ann Intern Med. 1995 Aug 1;123(3):195-204 [7598302.001]
  • [Cites] Int J Geriatr Psychiatry. 1998 Jul;13(7):433-9 [9695030.001]
  • [Cites] Arch Intern Med. 2005 Jan 10;165(1):68-74 [15642877.001]
  • [Cites] Am J Geriatr Pharmacother. 2004 Dec;2(4):248-56 [15903283.001]
  • [Cites] J Manag Care Pharm. 2005 Sep;11(7):575-83 [16137215.001]
  • [Cites] Am J Geriatr Pharmacother. 2006 Mar;4(1):36-41 [16730619.001]
  • [Cites] J Am Med Dir Assoc. 2007 Mar;8(3):173-7 [17349946.001]
  • [Cites] Isr Med Assoc J. 2007 Jun;9(6):430-4 [17642388.001]
  • [Cites] QJM. 2007 Nov;100(11):691-7 [17932098.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Feb;8(1):63-72 [20226393.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):901-10 [20623513.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Dec;8(6):562-70 [21356505.001]
  • [Cites] J Am Med Dir Assoc. 2011 Jun;12(5):326-30 [21450207.001]
  • [Cites] J Am Med Dir Assoc. 2012 Mar;13(3):309.e15-21 [21839687.001]
  • [Cites] J Am Geriatr Soc. 2012 Apr;60(4):616-31 [22376048.001]
  • [Cites] Clin Geriatr Med. 2012 May;28(2):199-216 [22500539.001]
  • [Cites] Clin Geriatr Med. 2012 May;28(2):217-36 [22500540.001]
  • [Cites] Clin Geriatr Med. 2012 May;28(2):237-53 [22500541.001]
  • [Cites] Clin Geriatr Med. 2012 May;28(2):323-41 [22500546.001]
  • [Cites] Clin Geriatr Med. 2012 May;28(2):xiii-xiv [22500547.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2012 Jun;67(6):698-704 [22219520.001]
  • [Cites] Arch Intern Med. 2001 Jul 9;161(13):1629-34 [11434795.001]
  • (PMID = 22959733.001).
  • [ISSN] 1538-9375
  • [Journal-full-title] Journal of the American Medical Directors Association
  • [ISO-abbreviation] J Am Med Dir Assoc
  • [Language] eng
  • [Grant] United States / PHS HHS / / 1K01HP20503; United States / NCRR NIH HHS / RR / 1R25RR019321; United States / NCRR NIH HHS / RR / R25 RR019321
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS398979; NLM/ PMC3489959
  •  go-up   go-down


8. Cooper IF, Siadaty MS: 'Hormones' associated with 'Polypharmacy Therapy': Top Publications. BioMedLib Review; Hormone;PolypharmacyTherapy:705227363. ISSN: 2331-5717. 2014/7/6
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Hormones' associated with 'Polypharmacy Therapy': Top Publications.
  • [Transliterated title]
  • Background: There are articles published each month which present 'Hormone' for 'polypharmacy therapy'.
  • Finding such articles is important for researchers, clinicians, and patients.
  • However these articles are spread across thousands of journals, and there are many types of 'Hormone'.
  • This makes searching and locating the relevant publications a challenge.
  • We have used BioMedLib's semantic search technology to address the issue, and gathered all the pertinent publications in this review article.
  • Methods: We categorized the publications we found into two groups.
  • We used the strength of textual-association to separate the groups.
  • In group one there are publications with the strongest evidence of association. We focused finding the most relevant publications pertinent to our goal, rather than combining them into a conclusion section. Such textual synthesis will be the focus of our next project.
  • Results: Group one includes 33 publications, and group two 865 publications.
  • Here are the top 10.
  • Cooper IF et al: 'Hormones' associated with 'Polypharmacy Finding': Top Publications.
  • Gleason LJ et al: Polypharmacy in the HIV-infected older adult population.
  • Kowatch RA et al: Prescription of psychiatric medications and polypharmacy in the LAMS cohort.
  • Lee HW et al: The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release.
  • Steinsvoll PS: [Polypharmacy in the elderly].
  • Sehgal V et al: Polypharmacy and potentially inappropriate medication use as the precipitating factor in readmissions to the hospital.
  • Mazzocato C et al: [Polypharmacy and the elderly: neither too much nor too little].
  • Franchi C et al: Geographical differences in the prevalence of chronic polypharmacy in older people: eleven years of the EPIFARM-Elderly Project.
  • Onder G et al: Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: results from the SHELTER study.
  • Sganga F et al: Physical Performance Measures and Polypharmacy among Hospitalized Older Adults: Results from the CRIME Study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 705227363.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


9. Cooper IF, Siadaty MS: 'Pathologic Functions' associated with 'Polypharmacy Therapy': Top Publications. BioMedLib Review; PathologicFunction;PolypharmacyTherapy:706829683. ISSN: 2331-5717. 2014/12/1
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Pathologic Functions' associated with 'Polypharmacy Therapy': Top Publications.
  • [Transliterated title]
  • Background: There are articles published each month which present 'Pathologic Function' for 'polypharmacy therapy'.
  • Finding such articles is important for researchers, clinicians, and patients.
  • However these articles are spread across thousands of journals, and there are many types of 'Pathologic Function'.
  • This makes searching and locating the relevant publications a challenge.
  • We have used BioMedLib's semantic search technology to address the issue, and gathered all the pertinent publications in this review article.
  • Methods: We categorized the publications we found into two groups.
  • We used the strength of textual-association to separate the groups.
  • In group one there are publications with the strongest evidence of association. We focused finding the most relevant publications pertinent to our goal, rather than combining them into a conclusion section. Such textual synthesis will be the focus of our next project.
  • Results: Group one includes 18 publications, and group two 2272 publications.
  • Here are the top 10.
  • Hogan DB: Revisiting the O complex: urinary incontinence, delirium and polypharmacy in elderly patients.
  • Loyola Filho AI et al: [Influence of income on the association between cognitive impairment and polypharmacy: Bambuí Project].
  • Willey CJ et al: Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control.
  • Hussain A et al: After more than 300 defibrillation shocks, patient still alive 12 years later refractory torsade de pointes due to polypharmacy and persistent vomiting.
  • Stahl SM: Emerging guidelines for the use of antipsychotic polypharmacy.
  • Bhatnagar M et al: A 61-year-old with bipolar disorder and cognitive impairment: dementia or polypharmacy?.
  • Grundy SM: Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
  • Myers LW et al: Polypharmacy in multiple sclerosis.
  • Vigouroux C et al: Emerging clinical issues related to management of multiorgan comorbidities and polypharmacy.
  • Moss L et al: Exploring polypharmacy in elderly women after myocardial infarction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 706829683.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


10. Zadak Z, Hyspler R, Ticha A, Vlcek J: Polypharmacy and malnutrition. Curr Opin Clin Nutr Metab Care; 2013 Jan;16(1):50-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy and malnutrition.
  • PURPOSE OF REVIEW: Malnutrition and polypharmacy increase with age and polymorbidity and their relationship is based on a number of mechanisms.
  • The occurrence of malnutrition in both in-patients and out-patients and its dependence on polymorbidity and age are well known, but the interrelation of polypharmacy and malnutrition has been far less investigated.
  • The countries with the highest occurrence of polypharmacy in Europe include the Czech Republic and Finland, whereas the lowest prevalence of polypharmacy is found in Norway and the Netherlands.
  • RECENT FINDINGS: The occurrence, consequences and mutual relationship of malnutrition and polypharmacy are described.
  • SUMMARY: The effect of polypharmacy on nutrition is suggested from the observations that problems with nutrition occur mostly in elderly patients, and that such patients are more frequently subject to polypharmacy.
  • [MeSH-major] Elder Nutritional Physiological Phenomena. Malnutrition / epidemiology. Polypharmacy

  • MedlinePlus Health Information. consumer health - Malnutrition.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23201650.001).
  • [ISSN] 1473-6519
  • [Journal-full-title] Current opinion in clinical nutrition and metabolic care
  • [ISO-abbreviation] Curr Opin Clin Nutr Metab Care
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


11. von Lueder TG, Atar D: Comorbidities and polypharmacy. Heart Fail Clin; 2014 Apr;10(2):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidities and polypharmacy.
  • Polypharmacy in HF is common, has increased throughout the past 2 decades, and may pose a risk for adverse drug interactions, accidental overdosing, or medication nonadherence.
  • Polypharmacy, in particular in the elderly, is rarely assessed in traditional clinical trials, highlighting a need for entirely novel HF research strategies.
  • [MeSH-major] Heart Failure / complications. Heart Failure / drug therapy. Polypharmacy

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • ResearchGate. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2014 Elsevier Inc. All rights reserved.
  • (PMID = 24656112.001).
  • [ISSN] 1551-7136
  • [Journal-full-title] Heart failure clinics
  • [ISO-abbreviation] Heart Fail Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Comorbidities / Elderly / Heart failure / Polypharmacy
  •  go-up   go-down


12. Talasz H, Lechleitner M: Polypharmacy and incontinence. Z Gerontol Geriatr; 2012 Aug;45(6):464-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy and incontinence.
  • Polypharmacy as well as urinary incontinence are common geriatric problems.
  • The occurrence or aggravation of lower urinary tract symptoms might be caused by medication, especially when the symptom is newly diagnosed.
  • Especially antimuscarinic drugs reveal several complex anticholinergic adverse effects.
  • Therefore, knowledge of inappropriate medication and of possible adverse drug effects is important in the diagnostic evaluation and therapeutic considerations to prevent a cascade of symptom-related medications.
  • [MeSH-major] Drug Interactions. Drug-Related Side Effects and Adverse Reactions / epidemiology. Polypharmacy. Urinary Incontinence / epidemiology

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22767398.001).
  • [ISSN] 1435-1269
  • [Journal-full-title] Zeitschrift für Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Zink M, Englisch S, Meyer-Lindenberg A: Polypharmacy in schizophrenia. Curr Opin Psychiatry; 2010 Mar;23(2):103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy in schizophrenia.
  • RECENT FINDINGS: Polypharmacy intends to address different aspects of treatment resistance, most importantly insufficient response of psychotic positive and negative symptoms, but also cognitive disturbances, affective comorbidity, obsessive-compulsive syndromes and side-effects of antipsychotic drugs.
  • For treatment-resistant cognitive symptoms, antipsychotic medication should be combined with cognitive remediation, as no pharmacological add-on strategy has gained convincing evidence so far.
  • [MeSH-major] Antipsychotic Agents / therapeutic use. Polypharmacy. Schizophrenia / drug therapy

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20051861.001).
  • [ISSN] 1473-6578
  • [Journal-full-title] Current opinion in psychiatry
  • [ISO-abbreviation] Curr Opin Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Number-of-references] 126
  •  go-up   go-down


14. Zink M, Englisch S, Meyer-Lindenberg A: [Polypharmacy in schizophrenia]. Nervenarzt; 2011 Jul;82(7):853-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy in schizophrenia].
  • [Transliterated title] Polypharmazie bei schizophrenen Psychosen.
  • RESULTS: Polypharmacy aims to address several aspects of treatment resistance and side effects of antipsychotics.
  • [MeSH-major] Antidepressive Agents / administration & dosage. Antimanic Agents / administration & dosage. Antipsychotic Agents / administration & dosage. Polypharmacy. Schizophrenia / drug therapy

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21165589.001).
  • [ISSN] 1433-0407
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antimanic Agents; 0 / Antipsychotic Agents
  •  go-up   go-down


15. Kaufman G: Polypharmacy in older adults. Nurs Stand; 2011 May 25-31;25(38):49-55; quiz 58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy in older adults.
  • This article explores the issue of polypharmacy in older adults.
  • The risks of adverse drug reactions and adverse drug interactions linked to polypharmacy are explored.
  • [MeSH-major] Polypharmacy

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21706978.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Gosch M, Jeske M, Kammerlander C, Roth T: Osteoporosis and polypharmacy. Z Gerontol Geriatr; 2012 Aug;45(6):450-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoporosis and polypharmacy.
  • Due to drug interactions and patient compliance, polypharmacy is often mentioned as a reason for undertreatment.
  • However, patients with a polypharmacy are at a higher risk of fractures and should receive osteoporosis treatment, if indicated.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Drug Interactions. Drug-Related Side Effects and Adverse Reactions / epidemiology. Osteoporosis / epidemiology. Osteoporotic Fractures / epidemiology. Polypharmacy

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22806642.001).
  • [ISSN] 1435-1269
  • [Journal-full-title] Zeitschrift für Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents
  •  go-up   go-down


17. Gokula M, Holmes HM: Tools to reduce polypharmacy. Clin Geriatr Med; 2012 May;28(2):323-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tools to reduce polypharmacy.
  • The reduction in polypharmacy and avoidance of inappropriate medications is a common goal in the care of older persons, regardless of setting.
  • While multidisciplinary teams and regular medication reconciliation and review can identify and reduce medication-related problems, tools to decrease the use of high-risk/low benefit medications can help the individual clinician to improve prescribing.
  • Not all medication review instruments have been adequately validated, and the tools we have presented have varying levels of evidence to support their use.
  • Ultimately, optimizing prescribing by reducing polypharmacy and avoiding inappropriate medications is a highly individualized process for each patient, and clinicians will have to use extensive clinical judgment in using the tools presented here.
  • [MeSH-major] Drug Prescriptions / standards. Inappropriate Prescribing / prevention & control. Polypharmacy. Practice Guidelines as Topic

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22500546.001).
  • [ISSN] 1879-8853
  • [Journal-full-title] Clinics in geriatric medicine
  • [ISO-abbreviation] Clin. Geriatr. Med.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / K23AG038476
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  •  go-up   go-down


18. Strehblow C, Smeikal M, Fasching P: Polypharmacy and excessive polypharmacy in octogenarians and older acutely hospitalized patients. Wien Klin Wochenschr; 2014 Apr;126(7-8):195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy and excessive polypharmacy in octogenarians and older acutely hospitalized patients.
  • AIM: The aim of this study was to assess the occurrence of polypharmacy and excessive polypharmacy in very old hospitalized patients based on their comorbidities.
  • RESULTS: Chronic pulmonary disease [odds ratio (OR): 2.40], diabetes mellitus with (OR: 4.65) or without (OR: 1.65) microvascular complications, congestive heart failure (OR: 2.37), connective tissue disease (OR: 3.02), and peripheral vascular disease (OR: 2.30) were statistically significantly associated with polypharmacy, while some of these diseases were also associated with excessive polypharmacy.
  • "Admission for myocardial infarction" was associated with an increase in pharmaceuticals during hospital stay, whereas a known diagnosis of dementia or metastatic malignant disease was protective against a further increase in medications.
  • CONCLUSIONS: Several medical conditions seem to predispose to polypharmacy in very old patients.
  • Physicians should pay attention to the identified predictors in very old patients, as polypharmacy may lead to adverse events and unnecessary hospitalization.
  • [MeSH-major] Cardiovascular Diseases / drug therapy. Diabetes Mellitus / drug therapy. Drug Prescriptions / statistics & numerical data. Inappropriate Prescribing / statistics & numerical data. Length of Stay / statistics & numerical data. Lung Diseases / drug therapy. Polypharmacy

  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24445522.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


19. Yamanouchi Y: [How everyone recognize about polypharmacy?]. Seishin Shinkeigaku Zasshi; 2012;114(6):683-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [How everyone recognize about polypharmacy?].
  • This problem was discussed as quality of psychiatric medication by "the conference of the future about psychiatric health, medicine and welfare" (Japanese ministry of health, labor and welfare; 2009).
  • The report of this conference said "In order to accelerate improvement to single dosage and loss in quantity, we should be grasped of the actual condition about the polypharmacy and extensive medication of antipsychotics for schizophrenic patients, and we should be discussed about the methods of information and evaluation".
  • But there is no evidence about the polypharmacy is good or bad, and no one knows actual condition about the Japanese antipsychotics medications.
  • In order to answer this question, we are undergoing "the clinical study about safety and effective correction of polypharmacy and agent extensive medication of antipsychotics".
  • [MeSH-major] Antipsychotic Agents / administration & dosage. Drug Prescriptions / statistics & numerical data. Polypharmacy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22844819.001).
  • [ISSN] 0033-2658
  • [Journal-full-title] Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica
  • [ISO-abbreviation] Seishin Shinkeigaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


20. Chiang-Hanisko L, Tan JY, Chiang LC: [Polypharmacy issues in older adults]. Hu Li Za Zhi; 2014 Jun;61(3):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy issues in older adults].
  • Polypharmacy is a major concern in the care of older adults.
  • Polypharmacy is a term that refers to a high number of prescribed medications, usually five and above, or the use of more medications than is clinically justified.
  • Although medications are an important factor in improving and maintaining the quality of life of older adults, polypharmacy increases the risks of morbidity and mortality, loss of functional independence, and a multiplicity of cognitive and physical problems in this population.
  • This article examines issues related to polypharmacy in older adults and identifies nursing strategies and interventions to detect and prevent polypharmacy.
  • (1) increasing patient knowledge of pharmacological issues, (2) increasing patient medication management competency, (3) promoting safe patient medication practices, and (4) enhancing patient education.
  • [MeSH-major] Nurse's Role. Polypharmacy
  • [MeSH-minor] Aged. Humans. Medication Therapy Management. Patient Education as Topic. Patient Medication Knowledge

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24899563.001).
  • [ISSN] 0047-262X
  • [Journal-full-title] Hu li za zhi The journal of nursing
  • [ISO-abbreviation] Hu Li Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Keywords] NOTNLM ; older adults / polypharmacy
  •  go-up   go-down


21. Hovstadius B, Petersson G: Factors leading to excessive polypharmacy. Clin Geriatr Med; 2012 May;28(2):159-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors leading to excessive polypharmacy.
  • There are numerous risk factors for patients to develop excessive polypharmacy.
  • Risk factors associated with patient behavior, such as patient’s self medication with all types of medications, have not been observed to the same extent but might be at the same level of importance for patients developing excessive polypharmacy.
  • The few studies conducted regarding the large variation in physicians’ individual prescribing practices, in terms of polypharmacy, add another perspective to the complexity of the area.
  • Interventions aiming to improve communication between GP and hospital specialist, to create support systems for medical reviews that include all patients’ medications, and to improve the knowledge of multiple prescribing might have the largest potential to better manage excessive polypharmacy.
  • [MeSH-major] Pharmaceutical Preparations / administration & dosage. Physician's Practice Patterns. Polypharmacy. Self Medication

  • MedlinePlus Health Information. consumer health - Medicines.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22500536.001).
  • [ISSN] 1879-8853
  • [Journal-full-title] Clinics in geriatric medicine
  • [ISO-abbreviation] Clin. Geriatr. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  •  go-up   go-down


22. Flahaut J: [The theriac Diatessaron; oligopharmacy against polypharmacy]. Rev Hist Pharm (Paris); 2010 Oct;58(367):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The theriac Diatessaron; oligopharmacy against polypharmacy].
  • [Transliterated title] La thériaque Diatessaron Oligopharmacie contre polypharmacie.
  • The theriac of Andromachus was the symbol of polypharmacy and the theriac Diatessaron was a product of oligopharmacy.
  • [MeSH-major] Antidotes / history. Materia Medica / history. Pharmacy / history
  • [MeSH-minor] History, 18th Century. Phytotherapy / history. Polypharmacy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21560364.001).
  • [ISSN] 0035-2349
  • [Journal-full-title] Revue d'histoire de la pharmacie
  • [ISO-abbreviation] Rev Hist Pharm (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antidotes; 0 / Materia Medica
  •  go-up   go-down


23. Sommeregger U, Iglseder B, Böhmdorfer B, Benvenuti-Falger U, Dovjak P, Lechleitner M, Otto R, Roller RE, Gosch M: [Polypharmacy and falls in the Elderly]. Wien Med Wochenschr; 2010 Jun;160(11-12):293-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy and falls in the Elderly].
  • [Transliterated title] Polypharmazie und Stürze im Alter.
  • Main causes are the combination of age-related physiological changes with multimorbidity and subsequent polypharmacy.

  • MedlinePlus Health Information. consumer health - Falls.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20640927.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Prescription Drugs
  •  go-up   go-down


24. Holmes HM: Polypharmacy. Clin Geriatr Med; 2012 May;28(2):xiii-xiv
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy.
  • [MeSH-major] Polypharmacy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22500547.001).
  • [ISSN] 1879-8853
  • [Journal-full-title] Clinics in geriatric medicine
  • [ISO-abbreviation] Clin. Geriatr. Med.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / K23 AG038476
  • [Publication-type] Editorial
  • [Publication-country] United States
  •  go-up   go-down


25. Taylor D: Polypharmacy. Nurs Stand; 2011 Oct 26-Nov 1;26(8):59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy.
  • [MeSH-major] Polypharmacy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22165808.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Ingham G: Polypharmacy. Nurs Stand; 2012 Apr 25-May 1;26(34):59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy.
  • [MeSH-major] Drug Therapy. Polypharmacy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22787875.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Jesson B: Minimising the risk of polypharmacy. Nurs Older People; 2011 May;23(4):14-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimising the risk of polypharmacy.
  • Polypharmacy holds particular risks for the older population, which nurses are in a good position to recognise and minimise.
  • The aim of this article is to highlight the reasons why polypharmacy presents such a risk to older people and to consider what actions can be taken to address this problem.
  • [MeSH-major] Polypharmacy. Risk Reduction Behavior

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21675164.001).
  • [ISSN] 1472-0795
  • [Journal-full-title] Nursing older people
  • [ISO-abbreviation] Nurs Older People
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Thürmann PA: [Polypharmacy]. MMW Fortschr Med; 2014 May 28;156(10):56-61; quiz 62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy].
  • [Transliterated title] Polypharmazie. Treiben Sie den Teufel nicht mit dem Beelzebub aus!

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24930234.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


29. Suchopár J, Prokes M: [Polypharmacy and drug interactions]. Vnitr Lek; 2011 Sep;57(9):755-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy and drug interactions].
  • [Transliterated title] Polypragmazie a lékové interakce.
  • The growing consumption of drugs and other numerous factors relates to the increasing incidence of polypharmacy.
  • Some works show that it is possible to satisfactorily address the issues of polypharmacy, but it requires great courage and an interdisciplinary approach involving modern information technology.
  • [MeSH-major] Drug Interactions. Polypharmacy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21957770.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


30. Planton J, Edlund BJ: Strategies for reducing polypharmacy in older adults. J Gerontol Nurs; 2010 Jan;36(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies for reducing polypharmacy in older adults.
  • Polypharmacy is a major concern in the care of older adults.
  • Further, identifying those individuals at risk for medication problems, as well as implementing specific strategies in practice to reduce the problem, will enable clinicians to develop safe and evidence-based medication regimens that minimize the risk of adverse drug reactions.
  • The key to treating older adults is not necessarily to find a set number of medications and try to stay below it, but to find the right medication at the right dosage and for the shortest possible duration on a case-by-case basis.
  • [MeSH-major] Geriatric Nursing / organization & administration. Polypharmacy. Safety Management / organization & administration

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010, SLACK Incorporated.
  • (PMID = 20047247.001).
  • [ISSN] 0098-9134
  • [Journal-full-title] Journal of gerontological nursing
  • [ISO-abbreviation] J Gerontol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Barnes TR, Paton C: Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs; 2011 May;25(5):383-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antipsychotic polypharmacy in schizophrenia: benefits and risks.
  • Antipsychotic polypharmacy refers to the co-prescription of more than one antipsychotic drug for an individual patient.
  • The relatively widespread use of antipsychotic polypharmacy identified in cross-sectional surveys reflects not only the addition of a second antipsychotic to boost therapeutic response, but also the use of as-required antipsychotic medication (mainly to treat disturbed behaviour), gradual cross-titration while switching from one antipsychotic to another, and augmentation of clozapine with a second antipsychotic where the illness has failed to respond adequately to an optimized trial of clozapine.
  • Also reviewed are examples of systematic, practice-based interventions designed to reduce the prevalence of antipsychotic polypharmacy, most of which have met with only modest success.
  • [MeSH-minor] Drug Therapy, Combination. Female. Guidelines as Topic. Humans. Male. Physician's Practice Patterns. Polypharmacy


32. Mannucci PM, Nobili A, REPOSI Investigators: Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern Emerg Med; 2014 Oct;9(7):723-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimorbidity and polypharmacy in the elderly: lessons from REPOSI.
  • The main goals of the registry were to evaluate drug prescription appropriateness, the relationship between multimorbidity/polypharmacy and such cogent outcomes as hospital mortality and re-hospitalization, and the identification of disease clusters that most often concomitantly occur in the elderly.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25164413.001).
  • [ISSN] 1970-9366
  • [Journal-full-title] Internal and emergency medicine
  • [ISO-abbreviation] Intern Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Investigator] Mannucci PM; Nobili A; Tettamanti M; Pasina L; Franchi C; Salerno F; Corrao S; Marengoni A; Marcuccim M; Sparacio E; Alborghetti S; Di Costanzo R; Eldin TK; Tettamanti M; Djade CD; Prisco D; Silvestri E; Cenci C; Barnini T; Firenze C; Delitala G; Carta S; Atzori S; Guarnieri G; Zanetti M; Spalluti A; Serra MG; Bleve MA; Panico C; Vanoli M; Grignani G; Casella G; Gasbarrone L; Maniscalco G; Gunelli M; Tirotta D; Brucato A; Ghidoni S; Bernardi M; Li Bassi S; Santi L; Agnelli G; Iorio A; Marcucci M; Marchesini E; Mannarino E; Lupattelli G; Rondelli P; Paciullo F; Fabris F; Carlon M; Turatto F; Baroni MC; Zardo M; Manfredini R; Molino C; Pala M; Fabbian F; Nuti R; Valenti R; Ruvio M; Cappelli S; Paolisso G; Rizzo MR; Laieta MT; Nutrizionali M; Salvatore T; Sasso FC; Utili R; Durante Mangoni E; Pinto D; Infettivologica M; Olivieri O; Stanzial AM; Fellin R; Volpato S; Fotini S; Barbagallo M; Dominguez L; Plances L; D'Angelo D; Rini G; Mansueto P; Pepe I; Licata G; Calvo L; Valenti M; Borghi C; Strocchi E; Rinaldi ER; Zoli M; Fabbri E; Magalotti D; Auteri A; Pasqui AL; Puccetti L; Pasini FL; Capecchi PL; Bicchi M; Sabba C; Vella FS; Marseglia A; Luglio CV; Palasciano G; Modeo ME; Aquilino A; Raffaele P; Pugliese S; Capobianco C; Murri IA; Postiglione A; Barbella MR; De Stefano F; Fenoglio L; Brignone C; Bracco C; Giraudo A; Musca G; Cuccurullo O; Cricco L; Fiorentini A; Cappellini MD; Fabio G; Seghezzi S; De Amicis MM; Fargion S; Bonara P; Bulgheroni M; Lombardi R; Magrini F; Massari F; Tonella T; Peyvandi F; Tedeschi A; Rossio R; Moreo G; Ferrari B; Roncari L; Monzani V; Savojardo V; Folli C; Magnini M; Mari D; Rossi PD; Damanti S; Prolo S; Lilleri MS; Cricco L; Fiorentini A; Micale G; Podda M; Selmi C; Meda F; Salerno F; Accordino S; Conca A; Monti V; Corazza GR; Miceli E; Lenti MV; Padula D; Balduini CL; Bertolino G; Provini S; Quaglia F; Murialdo G; Bovio M; Dallegri F; Ottonello L; Quercioli A; Barreca A; Secchi MB; Ghelfi D; Balsamo C; Chin WS; Carassale L; Caporotundo S; Anastasio L; Sofia L; Carbone M; Valentia V; Traisci G; De Feudis L; Di Carlo S; Davì G; Guagnano MT; Sestili S; Bergami E; Rizzioli E; Cagnoni C; Bertone L; Manucra A; Soccorso P; Buratti A; Tognin T; Liberato NL; Bernasconi G; Nardo B; Bianchi GB; Giaquinto S; Benetti G; Quagliolo M; Centenaro GR; Predabissi V; Purrello F; Di Pino A; Piro S; Mancuso G; Calipari D; Bartone M; Gullo F; Cortellaro M; Magenta M; Perego F; Meroni MR; Cicardi M; Marina Magenta AG; Sacco A; Bonelli A; Dentamaro G; Rozzini R; Falanga L; Giordano A; Perin PC; Lorenzati B; Gruden G; Bruno G; Montrucchio G; Greco E; Tizzani P; Fera G; Di Luca ML; Renna D; Perciccante A; Coralli A; Tassara R; Melis D; Rebella L; Menardo G; Bottone S; Sferrazzo E; Ferri C; Striuli R; Scipioni R; Salmi R; Gaudenzi P; Gamberini S; Ricci F; Morabito C; Semplicini A; Gottardo L; Delitala G; Carta S; Atzori S; Vendemiale G; Serviddio G; Forlano R; Bolondi L; Rasciti L; Serio I; Masala C; Mammarella A; Raparelli V; Rossi Fanelli F; Delfino M; Amoroso A; Violi F; Basili S; Perri L; Serra P; Fontana V; Falcone M; Landolfi R; Grieco A; Gallo A; Zuccalà G; Franceschi F; De Marco G; Chiara C; Marta S; Bellusci M; Setti D; Pedrazzoli F; Romanelli G; Pirali C; Amolini C; Rosei EA; Rizzoni D; Castoldi L; Picardi A; Gentilucci UV; Mazzarelli C; Gallo P; Guasti L; Castiglioni L; Maresca A; Squizzato A; Contini S; Molaro M; Annoni G; Corsi M; Zazzetta S; Bertolotti M; Mussi C; Scotto R; Ferri MA; Veltri F; Arturi F; Succurro E; Sesti G; Gualtieri U; Grecia SM; Perticone F; Sciacqua A; Quero M; Bagnato C; Loria P; Becchi MA; Martucci G; Fantuzzi A; Maurantonio M; Corinaldesi R; De Giorgio R; Serra M; Grasso V; Ruggeri E; Carozza LM; Pignatti F
  •  go-up   go-down


33. Maggiore RJ, Gross CP, Hurria A: Polypharmacy in older adults with cancer. Oncologist; 2010;15(5):507-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy in older adults with cancer.
  • The definition of "polypharmacy" ranges from the use of a large number of medications; the use of potentially inappropriate medications, which can increase the risk for adverse drug events; medication underuse despite instructions to the contrary; and medication duplication.
  • In this review, we outline the adverse outcomes associated with polypharmacy and present polypharmacy definitions offered by the geriatrics literature.
  • We also examine the strengths and weaknesses of these definitions and explore the relationships among these definitions and what is known about the prevalence and impact of polypharmacy.
  • [MeSH-major] Neoplasms / drug therapy. Polypharmacy

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharm World Sci. 2007 Jun;29(3):109-15 [17353970.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):658-67 [16906628.001]
  • [Cites] J Altern Complement Med. 2007 Jun;13(5):555-62 [17604560.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Mar;5(1):40-7 [17608246.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Jun;5(2):147-61 [17719517.001]
  • [Cites] Am J Emerg Med. 2007 Sep;25(7):804-7 [17870486.001]
  • [Cites] Ann Pharmacother. 2007 Oct;41(10):1617-24 [17785609.001]
  • [Cites] J Am Geriatr Soc. 2007 Oct;55 Suppl 2:S247-52 [17910544.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2007 Oct;62(10):1172-81 [17921433.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Dec;5(4):345-51 [18179993.001]
  • [Cites] Drugs Aging. 2008;25(1):49-59 [18184029.001]
  • [Cites] Integr Cancer Ther. 2008 Sep;7(3):122-9 [18956493.001]
  • [Cites] Curr Treat Options Oncol. 2008 Jun;9(2-3):191-203 [18663583.001]
  • [Cites] Age Ageing. 2008 Nov;37(6):673-9 [18829684.001]
  • [Cites] JAMA. 2008 Dec 24;300(24):2867-78 [19109115.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Jan;18(1):53-61 [19111015.001]
  • [Cites] Arch Gerontol Geriatr. 2009 Mar-Apr;48(2):186-90 [18313773.001]
  • [Cites] Eur J Clin Pharmacol. 2009 Feb;65(2):199-207 [18807252.001]
  • [Cites] Drugs Aging. 2009;26(2):123-33 [19220069.001]
  • [Cites] Am J Geriatr Pharmacother. 2009 Feb;7(1):20-5 [19281937.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2009 May;64(5):599-609 [19264957.001]
  • [Cites] Ann Pharmacother. 2009 Feb;43(2):177-84 [19193583.001]
  • [Cites] Am J Geriatr Pharmacother. 2009 Apr;7(2):84-92 [19447361.001]
  • [Cites] J Am Geriatr Soc. 2009 Jun;57(6):1007-14 [19467144.001]
  • [Cites] Am J Geriatr Pharmacother. 2009 Jun;7(3):151-8 [19616183.001]
  • [Cites] Arch Intern Med. 2009 Jul 27;169(14):1326-32 [19636035.001]
  • [Cites] BMC Geriatr. 2009;9:30 [19627577.001]
  • [Cites] Age Ageing. 2009 Sep;38(5):603-6 [19435757.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2642-8 [10594859.001]
  • [Cites] Acad Emerg Med. 1999 Dec;6(12):1232-42 [10609925.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 5;92(1):42-7 [10620632.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2000 Feb;55(2):M57-63 [10737686.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] Oncol Nurs Forum. 2000 May;27(4):623-30 [10833691.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2505-14 [10893280.001]
  • [Cites] Arch Intern Med. 2000 Jul 24;160(14):2129-34 [10904455.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2000 Oct;55(10):M554-9 [11034227.001]
  • [Cites] J Altern Complement Med. 2000 Dec;6(6):531-8 [11152058.001]
  • [Cites] J Am Geriatr Soc. 2001 Feb;49(2):200-9 [11207875.001]
  • [Cites] Ann Pharmacother. 2001 May;35(5):539-45 [11346058.001]
  • [Cites] Am J Clin Nutr. 2001 Aug;74(2):201-5 [11470721.001]
  • [Cites] Ann Pharmacother. 2001 Sep;35(9):1004-9 [11573845.001]
  • [Cites] J Intern Med. 2001 Oct;250(4):327-41 [11576320.001]
  • [Cites] Oncology (Williston Park). 2001 Oct;15(10):1267-72; discussion 1272-8, 1283 [11702957.001]
  • [Cites] JAMA. 2001 Dec 12;286(22):2823-9 [11735757.001]
  • [Cites] Med Care. 2002 Feb;40(2):166-76 [11802089.001]
  • [Cites] Gynecol Oncol. 2002 Mar;84(3):363-7 [11855870.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1187-8 [12189216.001]
  • [Cites] J Altern Complement Med. 2002 Aug;8(4):477-85 [12230908.001]
  • [Cites] Am J Public Health. 2002 Oct;92(10):1606-9 [12356606.001]
  • [Cites] J Altern Complement Med. 2002 Oct;8(5):661-71 [12470448.001]
  • [Cites] J Am Geriatr Soc. 2002 Dec;50(12):1962-8 [12473007.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1825-32 [1888249.001]
  • [Cites] J Am Geriatr Soc. 1991 Nov;39(11):1093-9 [1753048.001]
  • [Cites] Med Care. 1992 Jul;30(7):646-58 [1614233.001]
  • [Cites] J Clin Epidemiol. 1992 Oct;45(10):1045-51 [1474400.001]
  • [Cites] J Am Geriatr Soc. 1994 Dec;42(12):1241-7 [7983285.001]
  • [Cites] J Clin Epidemiol. 1994 Aug;47(8):891-6 [7730892.001]
  • [Cites] Can J Hosp Pharm. 1995 Jun;48(3):161-6 [10172367.001]
  • [Cites] Am J Med. 1996 Apr;100(4):428-37 [8610730.001]
  • [Cites] JAMA. 1997 Jan 8;277(2):115-21 [8990335.001]
  • [Cites] Ann Pharmacother. 1997 May;31(5):529-33 [9161643.001]
  • [Cites] Ann Pharmacother. 1997 May;31(5):543-8 [9161645.001]
  • [Cites] Arch Intern Med. 1997 Jul 28;157(14):1531-6 [9236554.001]
  • [Cites] Arch Intern Med. 1997 Aug 11-25;157(15):1681-6 [9250229.001]
  • [Cites] J Am Geriatr Soc. 1997 Aug;45(8):945-8 [9256846.001]
  • [Cites] Arch Intern Med. 1997 Oct 13;157(18):2089-96 [9382665.001]
  • [Cites] J Am Geriatr Soc. 1997 Nov;45(11):1360-1 [9361662.001]
  • [Cites] Dysphagia. 1998 Spring;13(2):69-81 [9513300.001]
  • [Cites] J Am Geriatr Soc. 1998 Jun;46(6):751-2 [9625192.001]
  • [Cites] Epidemiology. 1998 Jul;9(4):417-23 [9647906.001]
  • [Cites] J Am Geriatr Soc. 1998 Sep;46(9):1128-31 [9736107.001]
  • [Cites] Arch Intern Med. 1998 Oct 12;158(18):2024-8 [9778202.001]
  • [Cites] J Am Geriatr Soc. 1998 Nov;46(11):1423-4 [9809766.001]
  • [Cites] J Am Geriatr Soc. 1999 Jan;47(1):30-9 [9920227.001]
  • [Cites] J Am Geriatr Soc. 1999 Jan;47(1):40-50 [9920228.001]
  • [Cites] J Clin Pharm Ther. 1998 Dec;23(6):423-32 [10048503.001]
  • [Cites] N Engl J Med. 1999 Jun 3;340(22):1733-9 [10352166.001]
  • [Cites] Cancer Pract. 1999 May-Jun;7(3):136-44 [10352076.001]
  • [Cites] Eur J Clin Pharmacol. 1999 Sep;55(7):533-6 [10501824.001]
  • [Cites] Am J Geriatr Pharmacother. 2004 Jun;2(2):92-101 [15555485.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4810-5 [15570083.001]
  • [Cites] Arch Intern Med. 2005 Jan 10;165(1):68-74 [15642877.001]
  • [Cites] Eur J Clin Pharmacol. 2005 Nov;61(10):769-73 [16200422.001]
  • [Cites] Urology. 2005 Dec;66(6):1223-8 [16360447.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Jun;Suppl Web Exclusives:W5-152-W5-166 [15840625.001]
  • [Cites] BMC Geriatr. 2006;6:1 [16403236.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2006 Feb;61(2):170-5 [16510861.001]
  • [Cites] Geriatr Nurs. 2006 Mar-Apr;27(2):118-29 [16638483.001]
  • [Cites] Am J Med Qual. 2006 May-Jun;21(3):162-8 [16679435.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2006 May;61(5):511-5 [16720750.001]
  • [Cites] J Manag Care Pharm. 2006 Jun;12(5):362-70 [16792442.001]
  • [Cites] Am J Geriatr Pharmacother. 2006 Jun;4(2):134-43 [16860260.001]
  • [Cites] J Pain Symptom Manage. 2006 Aug;32(2):148-54 [16877182.001]
  • [Cites] J Manag Care Pharm. 2006 Sep;12(7):537-45 [16981799.001]
  • [Cites] Head Neck. 2006 Oct;28(10):926-31 [16755583.001]
  • [Cites] Am J Clin Oncol. 2006 Oct;29(5):468-73 [17023781.001]
  • [Cites] J Soc Integr Oncol. 2006 Fall;4(4):157-69 [17022924.001]
  • [Cites] J Am Geriatr Soc. 2006 Oct;54(10):1516-23 [17038068.001]
  • [Cites] BMC Complement Altern Med. 2006;6:34 [17026768.001]
  • [Cites] Drugs Aging. 2006;23(10):823-37 [17067185.001]
  • [Cites] J Am Geriatr Soc. 2006 Nov;54(11):1725-35 [17087700.001]
  • [Cites] Drugs Aging. 2006;23(11):915-24 [17109569.001]
  • [Cites] Pharm World Sci. 2006 Oct;28(5):296-301 [17111245.001]
  • [Cites] J Clin Pharm Ther. 2006 Dec;31(6):617-26 [17176367.001]
  • [Cites] Cancer Nurs. 2007 Jan-Feb;30(1):45-55; quiz 56-7 [17235219.001]
  • [Cites] Med Care. 2007 Jan;45(1):95-9 [17279026.001]
  • [Cites] Am J Geriatr Pharmacother. 2006 Dec;4(4):297-305 [17296535.001]
  • [Cites] Ann Pharmacother. 2007 Mar;41(3):438-47 [17311835.001]
  • [Cites] BMC Med Inform Decis Mak. 2007;7:7 [17346336.001]
  • [Cites] J Clin Pharm Ther. 2007 Apr;32(2):169-75 [17381667.001]
  • [Cites] Support Care Cancer. 2007 May;15(5):557-64 [17205277.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 18;99(8):592-600 [17440160.001]
  • [Cites] J Am Geriatr Soc. 2007 May;55(5):658-65 [17493184.001]
  • [Cites] J Support Oncol. 2007 Apr;5(4):195-8 [17500507.001]
  • [Cites] BMC Complement Altern Med. 2002 Aug 13;2:8 [12175424.001]
  • [Cites] Ann Intern Med. 2003 Nov 4;139(9):740-7 [14597458.001]
  • [Cites] Arch Intern Med. 2003 Dec 8-22;163(22):2716-24 [14662625.001]
  • [Cites] Altern Ther Health Med. 2004 Jan-Feb;10(1):52-7 [14727500.001]
  • [Cites] Ann Pharmacother. 2004 Jan;38(1):9-14 [14742785.001]
  • [Cites] Arch Intern Med. 2004 Feb 9;164(3):305-12 [14769626.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):671-7 [14966090.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1522-30 [15042688.001]
  • [Cites] J Am Pharm Assoc (2003). 2004 May-Jun;44(3):337-49 [15191244.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2489-503 [15197212.001]
  • [Cites] J Altern Complement Med. 2004 Jun;10(3):560-4 [15253863.001]
  • [Cites] Drugs Aging. 2005;22(1):69-82 [15663350.001]
  • [Cites] Ann Pharmacother. 2005 Mar;39(3):405-11 [15671088.001]
  • [Cites] Clin Ther. 2005 Jan;27(1):88-99 [15763610.001]
  • [Cites] Ann Pharmacother. 2005 Apr;39(4):643-8 [15741417.001]
  • [Cites] J Manag Care Pharm. 2005 Apr;11(3):211-9 [15804205.001]
  • [Cites] J Am Acad Nurse Pract. 2005 Apr;17(4):123-32 [15819637.001]
  • [Cites] Am J Geriatr Pharmacother. 2004 Dec;2(4):239-47 [15903282.001]
  • [Cites] Am J Geriatr Pharmacother. 2004 Dec;2(4):257-64 [15903284.001]
  • [Cites] Integr Cancer Ther. 2005 Jun;4(2):187-94 [15911931.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Sep;56(3):286-90 [15731916.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4719-25 [16034047.001]
  • [Cites] Br J Clin Pharmacol. 2005 Aug;60(2):137-44 [16042666.001]
  • [Cites] Eur J Clin Pharmacol. 2005 Jul;61(5-6):453-9 [15912391.001]
  • [Cites] J Am Geriatr Soc. 2005 Aug;53(8):1282-9 [16078952.001]
  • [Cites] J Am Geriatr Soc. 2005 Sep;53(9):1518-23 [16137281.001]
  • [Cites] Drugs Aging. 2005;22(9):767-77 [16156680.001]
  • [Cites] Support Care Cancer. 2005 Oct;13(10):806-11 [15711946.001]
  • [Cites] J Gerontol Nurs. 2005 Sep;31(9):4-11 [16190007.001]
  • [Cites] Support Care Cancer. 2005 Nov;13(11):912-9 [15856334.001]
  • [Cites] Am J Geriatr Pharmacother. 2005 Sep;3(3):168-79 [16257819.001]
  • [Cites] Oncol Nurs Forum. 2005 Nov;32(6):1115-22 [16270107.001]
  • [Cites] Age Ageing. 2008 Jan;37(1):96-101 [17933759.001]
  • [Cites] Res Nurs Health. 2008 Feb;31(1):42-51 [18163447.001]
  • [Cites] Int J Clin Pharmacol Ther. 2008 Feb;46(2):72-83 [18218287.001]
  • [Cites] Med Care. 2008 Feb;46(2):167-73 [18219245.001]
  • [Cites] J Am Diet Assoc. 2008 Mar;108(3):483-94 [18313431.001]
  • [Cites] Drugs Aging. 2008;25(4):343-55 [18361544.001]
  • [Cites] J Gen Intern Med. 2008 Apr;23(4):399-404 [18373136.001]
  • [Cites] J Gerontol Nurs. 2008 Apr;34(4):8-17 [18429375.001]
  • [Cites] Drugs Aging. 2005;22(10):877-85 [16245960.001]
  • [Cites] J Pain Symptom Manage. 2008 May;35(5):535-43 [18243638.001]
  • [Cites] Am J Emerg Med. 2008 Jul;26(6):697-700 [18606325.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2008 Jul;17(7):733-7 [18050360.001]
  • [Cites] Drugs Aging. 2008;25(8):683-92 [18665660.001]
  • [Cites] Drugs Aging. 2008;25(8):693-706 [18665661.001]
  • [Cites] Clin Interv Aging. 2008;3(2):383-9 [18686760.001]
  • [Cites] Ann Pharmacother. 2008 Jul;42(7):1017-25 [18594048.001]
  • [Cites] Am J Geriatr Pharmacother. 2008 Aug;6(3):147-52 [18775389.001]
  • [Cites] J Am Geriatr Soc. 2008 Jul;56(7):1306-11 [18482301.001]
  • [Cites] Oncology (Williston Park). 2008 Aug;22(9):1052-5, discussion 1055, 1058, 1060 [18777955.001]
  • [Cites] Drugs Aging. 2008;25(11):933-46 [18947261.001]
  • [Cites] Drugs Aging. 2008;25(11):947-54 [18947262.001]
  • [Cites] Pharmacotherapy. 2004 Jul;24(7):848-55 [15303449.001]
  • [Cites] J Altern Complement Med. 2004 Aug;10(4):660-6 [15353022.001]
  • [Cites] Drugs Aging. 2004;21(12):793-811 [15382959.001]
  • [Cites] Arch Intern Med. 2004 Oct 11;164(18):1957-9 [15477428.001]
  • [Cites] Arch Intern Med. 2004 Oct 11;164(18):2031-7 [15477439.001]
  • [Cites] Altern Ther Health Med. 2004 Sep-Oct;10(5):58-64 [15478787.001]
  • [Cites] J Am Geriatr Soc. 2004 Nov;52(11):1934-9 [15507075.001]
  • [Cites] J Am Geriatr Soc. 1988 Dec;36(12):1092-8 [3192887.001]
  • [Cites] DICP. 1990 Mar;24(3):321-3 [2316239.001]
  • [Cites] J Am Geriatr Soc. 1990 Oct;38(10):1082-7 [2229860.001]
  • [Cites] Chest. 1991 Apr;99(4):837-41 [2009784.001]
  • [Cites] Ann Pharmacother. 2003 Jan;37(1):40-6 [12503931.001]
  • [Cites] J Urol. 2003 Jul;170(1):166-9 [12796672.001]
  • [Cites] Drugs Aging. 2003;20(10):769-76 [12875612.001]
  • [Cites] Arch Intern Med. 2003 Oct 13;163(18):2165-72 [14557214.001]
  • (PMID = 20418534.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / 1 K08 AG24842; United States / NIA NIH HHS / AG / K23 AG026749-01; United States / NIA NIH HHS / AG / T32 AG19134
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 192
  • [Other-IDs] NLM/ PMC3227983
  •  go-up   go-down


34. Anthierens S, Tansens A, Petrovic M, Christiaens T: Qualitative insights into general practitioners views on polypharmacy. BMC Fam Pract; 2010;11:65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Qualitative insights into general practitioners views on polypharmacy.
  • BACKGROUND: Polypharmacy is common among older people.
  • The purpose of this study is to describe GPs' views and beliefs on polypharmacy in order to identify the role of the GP in relation to improving prescribing behaviour.
  • The aim of the study was to describe the GPs' perspectives on polypharmacy in primary care.
  • RESULTS: GPs acknowledge that polypharmacy is a problem in their older patient population, especially because of the risk of adverse drug reactions, interactions and lowered adherence.
  • GPs mention that difficulties in keeping an overview of the exact medication intake is an important problem caused by polypharmacy.
  • The patients' strong belief in their medication and self-medication are seen as important barriers in reducing the number of drugs taken.
  • Next to these patient related factors, there are some factors related to the prescriber, such as the lack of regular evaluation of the medication schedule by GPs and the involvement of several prescribers, especially in a hospital setting.
  • According to the respondents, prevention and evidence based medicine guidelines often induce polypharmacy.
  • CONCLUSIONS: GPs point out that polypharmacy is an important problem in their older patient population.
  • However, they do not have a readymade solution for polypharmacy.
  • The limited set of options for addressing polypharmacy leave GPs feeling powerless to tackle the problem.
  • [MeSH-major] Attitude of Health Personnel. Physicians, Family. Polypharmacy

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fam Pract. 2000 Jun;17(3):261-7 [10846147.001]
  • [Cites] J Clin Pharm Ther. 2009 Aug;34(4):369-76 [19583669.001]
  • [Cites] Ann Intern Med. 2001 May 15;134(10):997-1000 [11352700.001]
  • [Cites] Arch Intern Med. 2001 Jul 9;161(13):1629-34 [11434795.001]
  • [Cites] Ann Intern Med. 2001 Oct 16;135(8 Pt 2):642-6 [11601946.001]
  • [Cites] Pharm World Sci. 2002 Apr;24(2):46-54 [12061133.001]
  • [Cites] Arch Intern Med. 2002 Aug 12-26;162(15):1670-2 [12153368.001]
  • [Cites] Drugs Aging. 2003;20(11):817-32 [12964888.001]
  • [Cites] Arch Intern Med. 2004 Feb 9;164(3):305-12 [14769626.001]
  • [Cites] Nurse Educ Today. 2004 Feb;24(2):105-12 [14769454.001]
  • [Cites] Br J Clin Pharmacol. 2004 Mar;57(3):231-6 [14998418.001]
  • [Cites] BMJ. 2004 Aug 14;329(7462):367 [15310595.001]
  • [Cites] Arch Intern Med. 2004 Oct 11;164(18):1957-9 [15477428.001]
  • [Cites] J Clin Epidemiol. 1991;44(12):1353-9 [1753266.001]
  • [Cites] Res Nurs Health. 1995 Apr;18(2):179-83 [7899572.001]
  • [Cites] Am J Med. 1996 Apr;100(4):428-37 [8610730.001]
  • [Cites] Arch Intern Med. 1997 Jul 28;157(14):1531-6 [9236554.001]
  • [Cites] Qual Health Res. 2005 Nov;15(9):1277-88 [16204405.001]
  • [Cites] Soc Sci Med. 2006 Jul;63(1):54-63 [16427174.001]
  • [Cites] BMC Health Serv Res. 2006;6:72 [16764734.001]
  • [Cites] BMJ. 2006 Sep 2;333(7566):459-60 [16946321.001]
  • [Cites] Fam Pract. 2007 Feb;24(1):14-9 [17164234.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Mar;5(1):31-9 [17608245.001]
  • [Cites] Lancet. 2007 Jul 14;370(9582):173-84 [17630041.001]
  • [Cites] BMJ. 2008 Mar 15;336(7644):606-9 [18340075.001]
  • [Cites] BMJ. 2008 Apr 26;336(7650):950-1 [18397944.001]
  • [Cites] Res Nurs Health. 2000 Aug;23(4):334-40 [10940958.001]
  • (PMID = 20840795.001).
  • [ISSN] 1471-2296
  • [Journal-full-title] BMC family practice
  • [ISO-abbreviation] BMC Fam Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2945967
  •  go-up   go-down


35. Chen H, Patel A, Sherer J, Aparasu R: The definition and prevalence of pediatric psychotropic polypharmacy. Psychiatr Serv; 2011 Dec;62(12):1450-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The definition and prevalence of pediatric psychotropic polypharmacy.
  • OBJECTIVES: Using increasingly stringent criteria, this study evaluated the prevalence of psychotropic polypharmacy among children on the basis of duration of overlap between two or more psychotropic medications.
  • METHODS: The prevalence of psychotropic polypharmacy was defined as receiving ≥ 14 days, ≥ 30 days, ≥ 60 days, and ≥ 90 days of overlapping psychotropic prescription fills.
  • A sensitivity analysis was also conducted to explore the extent to which the cross-sectional operational definitions of polypharmacy used in the published literature identified patients who were prescribed psychotropic combinations on a long-term basis.
  • The observed rate of polypharmacy dropped to 27.2% with 30 days of overlap and to 20.9% with 60 days of overlap.
  • Using a 60-day overlap in psychotropic drugs as a cutoff between short-term and long-term polypharmacy, analyses showed that 14%-46% of patients identified by cross-sectional definitions as receiving polypharmacy had likely received combination treatment on a temporary rather than on a long-term basis.
  • In addition, cross-sectional definitions failed to identify 18%-44% of patients classified as receiving long-term polypharmacy (≥ 60-day overlap).
  • CONCLUSIONS: The observed rate of polypharmacy dropped with increasingly stringent operational definitions for polypharmacy.
  • The findings suggest that considerable differences arise when comparing rates of polypharmacy across studies with inconsistent operational definitions.
  • [MeSH-major] Drug Therapy, Combination / utilization. Mental Disorders / drug therapy. Polypharmacy. Psychotropic Drugs / therapeutic use

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22193792.001).
  • [ISSN] 1557-9700
  • [Journal-full-title] Psychiatric services (Washington, D.C.)
  • [ISO-abbreviation] Psychiatr Serv
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Psychotropic Drugs
  •  go-up   go-down


36. Suokas JT, Suvisaari JM, Haukka J, Korhonen P, Tiihonen J: Description of long-term polypharmacy among schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol; 2013 Apr;48(4):631-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Description of long-term polypharmacy among schizophrenia outpatients.
  • OBJECTIVE: This large nationwide study describes the prevalence and predictors of long-term antipsychotic polypharmacy among patients with schizophrenia.
  • Entry to the cohort was defined from the first hospitalization for schizophrenia during the years 2000-2007, and the date of assessment of antipsychotic polypharmacy was March 1, 2007.
  • Antipsychotic polypharmacy was defined as overlapping of two or more filled prescriptions of antipsychotics for over 60 days.
  • RESULTS: In a total 16,083 patients with schizophrenia the prevalence of antipsychotic polypharmacy was 46.2 % (N = 7,436, mean age 47.5 years, male 55 %).
  • The longer the duration of schizophrenia, the more common the antipsychotic polypharmacy.
  • Long index hospitalization and being male significantly associated with antipsychotic polypharmacy among all schizophrenia patients.
  • Especially, in chronic schizophrenia patients, the previous use of benzodiazepine like agents was associated with antipsychotic polypharmacy, but the use of antidepressants associated with less frequent antipsychotic polypharmacy.
  • CONCLUSIONS: Antipsychotic polypharmacy was widely prevalent among patients with schizophrenia and it was associated with long hospitalizations and long duration of illness.
  • Benzodiazepine use was associated with increased risk and antidepressant use with decreased risk of antipsychotic polypharmacy when the effect of other clinical and socioeconomic factors was adjusted.
  • Research is needed of risks and benefits of antipsychotic polypharmacy and augmentation of antipsychotic with other psychoactive drugs.
  • [MeSH-minor] Adult. Antidepressive Agents / therapeutic use. Benzodiazepines / therapeutic use. Cohort Studies. Drug Therapy, Combination. Female. Humans. Longitudinal Studies. Male. Middle Aged. Outpatients. Polypharmacy. Prevalence. Registries

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23007295.001).
  • [ISSN] 1433-9285
  • [Journal-full-title] Social psychiatry and psychiatric epidemiology
  • [ISO-abbreviation] Soc Psychiatry Psychiatr Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antipsychotic Agents; 12794-10-4 / Benzodiazepines
  •  go-up   go-down


37. Jyrkkä J, Mursu J, Enlund H, Lönnroos E: Polypharmacy and nutritional status in elderly people. Curr Opin Clin Nutr Metab Care; 2012 Jan;15(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy and nutritional status in elderly people.
  • PURPOSE OF REVIEW: Increasing use of drugs among elderly people has raised concerns about possible negative health outcomes, including malnutrition, associated with polypharmacy.
  • Evidence about the association of polypharmacy with nutritional status is scarce.
  • This review summarizes the relevant evidence regarding polypharmacy and nutritional status in elderly people.
  • Studies indicate also an association between polypharmacy and weight changes.
  • SUMMARY: On the basis of available evidence, the role of polypharmacy on nutritional status among elderly people is unclear.
  • Longitudinal studies with careful adjustment for underlying diseases are needed to explore association between polypharmacy and malnutrition.
  • [MeSH-major] Drug-Related Side Effects and Adverse Reactions. Malnutrition / etiology. Nutritional Status. Polypharmacy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Malnutrition.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22108093.001).
  • [ISSN] 1473-6519
  • [Journal-full-title] Current opinion in clinical nutrition and metabolic care
  • [ISO-abbreviation] Curr Opin Clin Nutr Metab Care
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


38. Peron EP, Ogbonna KC, Donohoe KL: Antidiabetic medications and polypharmacy. Clin Geriatr Med; 2015 Feb;31(1):17-27, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antidiabetic medications and polypharmacy.
  • Polypharmacy, or the use of multiple medications, is a serious concern for providers who care for older adults, as polypharmacy is associated with medication nonadherence, drug-drug interactions, drug-disease interactions, and adverse drug events.
  • Given high medication burden and potential for increased medication sensitivity in this patient population, it is prudent that providers are aware of potential risks and benefits of antidiabetic medications and implement shared decision-making practices to ensure appropriate care for older adults with diabetes.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2015 Elsevier Inc. All rights reserved.
  • (PMID = 25453298.001).
  • [ISSN] 1879-8853
  • [Journal-full-title] Clinics in geriatric medicine
  • [ISO-abbreviation] Clin. Geriatr. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adverse drug events / Diabetic complications / Geriatric syndromes / Hypoglycemic agents / Polypharmacy
  •  go-up   go-down


39. Lu J, Yang M, Luo L, Hao Q, Dong B: Polypharmacy among nonagenarians/centenarians in rural China. Intern Med J; 2014 Dec;44(12a):1193-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy among nonagenarians/centenarians in rural China.
  • BACKGROUND: Little is known about the prevalence and relevant factors of polypharmacy in nonagenarian and centenarians.
  • AIM: The aim of this study is to examine the prevalence and associated factors of polypharmacy in a sample of nonagenarians and centenarians living in a rural area of China.
  • Medication use and relevant covariates were obtained by face-to-face interviews.
  • Minor polypharmacy was defined as the concomitant use of two to four medications, whereas major polypharmacy referred to the concomitant use of five or more medications.
  • The prevalence of minor polypharmacy and major polypharmacy was 16.5% and 3.7% respectively.
  • Illiteracy (odds ratio (OR) 2.93, 95% confidence interval (CI) 1.52 to 5.66), cognitive impairment (OR 3.15, 95% CI 1.44 to 6.88), hypertension (OR 2.88, 95% CI 1.46 to 5.67), respiratory disease (OR 2.22, 95% CI 1.08 to 4.58), osteoarthritis (OR 1.24, 95% CI 1.01 to 1.51), and cancer (OR 10.70, 95% CI 1.90 to 126.80) were positively associated with minor polypharmacy.
  • Illiteracy (OR 4.24, 95% CI 1.53 to 11.81), hypertension (OR 3.40, 95% CI 1.22 to 9.49) and cancer (OR 3.40, 95% CI 1.14 to 10.12) were also positively associated with major polypharmacy.
  • CONCLUSIONS: Although most subjects suffer from some chronic diseases, minor polypharmacy and major polypharmacy are not common among nonagenarians/centenarians in rural China.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.
  • (PMID = 25039536.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Keywords] NOTNLM ; centenarian / chronic disease / epidemiology / nonagenarian / polypharmacy
  •  go-up   go-down


40. Xiang YT, Wang CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong KH, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N: Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009). Pharmacopsychiatry; 2012 Jan;45(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009).
  • OBJECTIVE: This study aimed to identify trends in the use of antipsychotic polypharmacy (APP) and their demographic and clinical correlates in the treatment of schizophrenia in Asia between 2001 and 2009.
  • [MeSH-major] Antipsychotic Agents / therapeutic use. Physician's Practice Patterns. Polypharmacy. Schizophrenia / drug therapy

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21989602.001).
  • [ISSN] 1439-0795
  • [Journal-full-title] Pharmacopsychiatry
  • [ISO-abbreviation] Pharmacopsychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Delayed-Action Preparations
  •  go-up   go-down


41. Volpe M, Chin D, Paneni F: The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol; 2010 Feb;24(1):9-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The challenge of polypharmacy in cardiovascular medicine.
  • However, the chronic use of five or more medications, defined as polypharmacy, has shown to be neither always efficacious nor safe.
  • Polypharmacy is associated with an increased morbidity and costs.
  • This review will focus on challenges of polypharmacy in CV medicine, illustrating potential options to face this emerging crisis.
  • [MeSH-major] Cardiovascular Agents / therapeutic use. Cardiovascular Diseases / drug therapy. Polypharmacy

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817871.001).
  • [ISSN] 1472-8206
  • [Journal-full-title] Fundamental & clinical pharmacology
  • [ISO-abbreviation] Fundam Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cardiovascular Agents
  • [Number-of-references] 83
  •  go-up   go-down


42. Díaz-Caneja CM, Espliego A, Parellada M, Arango C, Moreno C: Polypharmacy with antidepressants in children and adolescents. Int J Neuropsychopharmacol; 2014 Jul;17(7):1063-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy with antidepressants in children and adolescents.
  • A Medline search from inception until February 2012 was performed to identify epidemiological and clinical studies, reviews and reports containing potentially relevant information on polypharmacy with antidepressants in young people.
  • There has been an increase in polypharmacy in children and adolescents involving antidepressants in recent years.
  • Most information regarding efficacy and safety of polypharmacy patterns was provided by case series and open-label studies.
  • Adverse events were similar to those found with individual medication groups, with severe adverse events mostly reported by individual case reports.
  • The use of polypharmacy with antidepressants has become a regular practice in clinical settings.
  • Although there is still little efficacy and safety information, preliminary evidence points to the potential clinical usefulness of some polypharmacy patterns.
  • [MeSH-major] Antidepressive Agents / therapeutic use. Polypharmacy

  • MedlinePlus Health Information. consumer health - Antidepressants.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23190624.001).
  • [ISSN] 1469-5111
  • [Journal-full-title] The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)
  • [ISO-abbreviation] Int. J. Neuropsychopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Psychotropic Drugs
  •  go-up   go-down


43. Schaefer K, Maerkedahl H, Birk HO, Henriksen LO: Polypharmacy in general practice. Dan Med Bull; 2010 Jul;57(7):A4165
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy in general practice.
  • INTRODUCTION: Polypharmacy increases the risk of side effects and interactions.
  • We quantified the prevalence of major polypharmacy (MPP) in a Danish county with 236,000 inhabitants, invited general practitioners (GPs) to participate in a quality improvement project and discussed the medication of 10-20 MPP patients selected by the participating GPs.
  • CONCLUSIONS: MPP compromises the GP's ability to manage medication of individual patients.
  • Systematic audit of the total medication of patients should be introduced.
  • [MeSH-major] General Practice / statistics & numerical data. Polypharmacy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20591340.001).
  • [ISSN] 1603-9629
  • [Journal-full-title] Danish medical bulletin
  • [ISO-abbreviation] Dan Med Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


44. Mizokami F, Koide Y, Noro T, Furuta K: Polypharmacy with common diseases in hospitalized elderly patients. Am J Geriatr Pharmacother; 2012 Apr;10(2):123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy with common diseases in hospitalized elderly patients.
  • BACKGROUND: Elderly persons are exposed to polypharmacy because of multiple chronic conditions.
  • Many risk factors for polypharmacy have been identified including age, race/ethnicity, sex, educational achievement level, health status, and number of chronic diseases.
  • OBJECTIVE: The objective of this study was to analyze each common disease in the elderly with respect to prescribed drugs and polypharmacy.
  • The number of drugs and prevalence of polypharmacy were hypertension, 5.2 (3.9 [51%]); hyperlipidemia, 5.6 (3.8 [58%]); gastric ulcer, 5.4 (3.8 [53%]); previous stroke, 5.8 (3.2 [61%]); reflux esophagitis, 5.6 (3.8 [40%]), diabetes mellitus, 5.6 (3.1 [54%]); malignancy, 4.1 (3.1 [37%]); osteoporosis, 5.4 (3.4 [45%]); angina pectoris, 5.7 (3.6 [42%]); congestive heart failure, 6.1 (4.0 [60%]); chronic obstructive pulmonary disease, 5.0 (3.5 [53%]); dementia, 5.1 (3.2 [52%]); and depression, 7.0 (4.2 [73%]).
  • CONCLUSIONS: When assessing the risk of polypharmacy, physicians should carefully consider the type of any chronic disease.
  • Elderly patients with multiple diseases may be subjected to further polypharmacy.
  • [MeSH-major] Hospitalization / statistics & numerical data. Physician's Practice Patterns / statistics & numerical data. Polypharmacy. Prescription Drugs / therapeutic use

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.
  • (PMID = 22387105.001).
  • [ISSN] 1876-7761
  • [Journal-full-title] The American journal of geriatric pharmacotherapy
  • [ISO-abbreviation] Am J Geriatr Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prescription Drugs
  •  go-up   go-down


45. Dovjak P, Sommeregger U, Otto R, Roller RE, Böhmdorfer B, Iglseder B, Benvenuti-Falger U, Lechleitner M, Gosch M: [Polypharmacy is of major concern in cardiology]. Wien Med Wochenschr; 2010 Jun;160(11-12):264-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy is of major concern in cardiology].
  • [Transliterated title] Polypharmazie in der Kardiologie - ein beachtliches Problem bei Synkopen, QT-Zeit-Verlängerung, Bradykardie und Tachykardie.
  • Comorbidity and polypharmacy raise the need for clear concepts.

  • MedlinePlus Health Information. consumer health - Fainting.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • ResearchGate. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20640922.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Cardiovascular Agents; 0 / Prescription Drugs
  •  go-up   go-down


46. Heppner HJ, Christ M, Gosch M, Mühlberg W, Bahrmann P, Bertsch T, Sieber C, Singler K: Polypharmacy in the elderly from the clinical toxicologist perspective. Z Gerontol Geriatr; 2012 Aug;45(6):473-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy in the elderly from the clinical toxicologist perspective.
  • INTRODUCTION: Polypharmacy is closely associated with multimorbidity in the elderly and can lead to problems and drug interactions.
  • AIM: This study assessed polypharmacy in the elderly, tracking inquiries to the Poison Information Centre Nuremberg (PICN) and patients needing toxicological intensive care therapy.
  • [MeSH-major] Drug Interactions. Drug-Related Side Effects and Adverse Reactions / mortality. Poisoning / mortality. Polypharmacy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Poisoning.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22915001.001).
  • [ISSN] 1435-1269
  • [Journal-full-title] Zeitschrift für Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Hoffman DA, Schiller M, Greenblatt JM, Iosifescu DV: Polypharmacy or medication washout: an old tool revisited. Neuropsychiatr Dis Treat; 2011;7:639-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy or medication washout: an old tool revisited.
  • There has been a rapid increase in the use of polypharmacy in psychiatry possibly due to the introduction of newer drugs, greater availability of these newer drugs, excessive confidence in clinical trial results, widespread prescribing of psychotropic medications by primary care, and pressure to augment with additional medications for unresolved side effects or greater efficacy.
  • In fact, there may be additional safety risks with polypharmacy being so widespread.
  • Washout, as a clinical tool, is rarely done in medication management today.
  • Studies have shown that augmenting therapy with additional medications resulted in 9.1%-34.1% dropouts due to intolerance of the augmentation, whereas studies of medication washout demonstrated only 5.9%-7.8% intolerance to the washout procedure.
  • These perils justify reconsideration of medication washout before deciding on augmentation.
  • There are unwarranted fears and resistance in the medical community toward medication washout, especially at the moment a physician is trying to decide whether to washout or add more medications to the treatment regimen.
  • However, medication washout provides unique benefits to the physician: it establishes a new baseline of the disorder, helps identify medication efficacy from their adverse effects, and provides clarity of diagnosis and potential reduction of drug treatments, drug interactions, and costs.
  • After washout, physicians may be able to select the appropriate polypharmacy more effectively and safely, if necessary.
  • Washout, while not for every patient, may be an effective tool for physicians who need to decide on whether to add potentially risky polypharmacy for a given patient.
  • The risks of washout may, in some cases, be lower and the benefits may be clearly helpful for diagnosis, understanding medication effects, the doctor/patient relationship, and safer use of polypharmacy if indicated.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22090799.001).
  • [ISSN] 1178-2021
  • [Journal-full-title] Neuropsychiatric disease and treatment
  • [ISO-abbreviation] Neuropsychiatr Dis Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3215520
  • [Keywords] NOTNLM ; medication washout / polypharmacy / risk of polypharmacy
  •  go-up   go-down


48. Mastromarino V, Casenghi M, Testa M, Gabriele E, Coluccia R, Rubattu S, Volpe M: Polypharmacy in heart failure patients. Curr Heart Fail Rep; 2014 Jun;11(2):212-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy in heart failure patients.
  • In heart failure (HF), the progressive use of multiple drugs and a complex therapeutic regimen is common and is recommended by international guidelines.
  • Polypharmacy, defined as the chronic use of five or more medications, is an underestimated problem in the management of HF patients.
  • However, polypharmacy has an important impact on HF treatment, as it often leads to inappropriate drug prescription, poor adherence to pharmacological therapies, drug-drug interactions, and adverse effects.
  • [MeSH-major] Heart Failure / drug therapy. Polypharmacy
  • [MeSH-minor] Comorbidity. Delivery of Health Care / organization & administration. Drug Interactions. Drug Prescriptions / standards. Humans. Medication Adherence. Self Care / methods

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24493574.001).
  • [ISSN] 1546-9549
  • [Journal-full-title] Current heart failure reports
  • [ISO-abbreviation] Curr Heart Fail Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


49. Ravona-Springer R, Davidson M: Considerations in psychotropic treatments in dementia--can polypharmacy be avoided? Int J Neuropsychopharmacol; 2014 Jul;17(7):1107-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Considerations in psychotropic treatments in dementia--can polypharmacy be avoided?
  • Physicians treating demented individuals are confronted with complex clinical presentations.
  • In the present review, we discuss these factors in the context of polypharmacy and suggest further clinical and research strategies that may enable more accurate and less harmful therapeutic strategies.
  • [MeSH-major] Dementia / drug therapy. Polypharmacy. Psychotropic Drugs / therapeutic use
  • [MeSH-minor] Apathy / drug effects. Apathy / physiology. Caregivers. Humans. Psychotic Disorders / diagnosis. Psychotic Disorders / drug therapy. Psychotic Disorders / physiopathology. Sleep Initiation and Maintenance Disorders / diagnosis. Sleep Initiation and Maintenance Disorders / drug therapy. Sleep Initiation and Maintenance Disorders / physiopathology. Social Support

  • MedlinePlus Health Information. consumer health - Dementia.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23842111.001).
  • [ISSN] 1469-5111
  • [Journal-full-title] The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)
  • [ISO-abbreviation] Int. J. Neuropsychopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Psychotropic Drugs
  •  go-up   go-down


50. Cooper IF, Siadaty MS: 'Steroids' associated with 'Polypharmacy Therapy': Top Publications. BioMedLib Review; Steroid;PolypharmacyTherapy:705664151. ISSN: 2331-5717. 2014/4/25
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Steroids' associated with 'Polypharmacy Therapy': Top Publications.
  • [Transliterated title]
  • Background: There are articles published each month which present 'steroid' for 'polypharmacy therapy'.
  • Finding such articles is important for researchers, clinicians, and patients.
  • However these articles are spread across thousands of journals, and there are many types of 'steroid'.
  • This makes searching and locating the relevant publications a challenge.
  • We have used BioMedLib's semantic search technology to address the issue, and gathered all the pertinent publications in this review article.
  • Methods: We categorized the publications we found into two groups.
  • We used the strength of textual-association to separate the groups.
  • In group one there are publications with the strongest evidence of association. We focused finding the most relevant publications pertinent to our goal, rather than combining them into a conclusion section. Such textual synthesis will be the focus of our next project.
  • Results: Group one includes 38 publications, and group two 748 publications.
  • Here are the top 10.
  • Gleason LJ et al: Polypharmacy in the HIV-infected older adult population.
  • Reason B et al: The impact of polypharmacy on the health of Canadian seniors.
  • Lee HW et al: The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release.
  • Jenny JL et al: Nurses opinion on the attributes of polypharmacy in patient safety.
  • Carvalho MF et al: Polypharmacy among the elderly in the city of São Paulo, Brazil - SABE Study.
  • Sehgal V et al: Polypharmacy and potentially inappropriate medication use as the precipitating factor in readmissions to the hospital.
  • Steinsvoll PS: [Polypharmacy in the elderly].
  • Heppner HJ et al: Polypharmacy in the elderly from the clinical toxicologist perspective.
  • Mazzocato C et al: [Polypharmacy and the elderly: neither too much nor too little].
  • Mansur N et al: Looking beyond polypharmacy: quantification of medication regimen complexity in the elderly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 705664151.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


top


2. Definitions


3. Related RMF webpages


terms of use | advertising programs | contact us
© 2015 RecentMedicalFindings


Connect with the


RMF


audience;




Post your ad here!